"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. . "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. bethanechol. this classification denotes an antimuscarinic agent with the molecular formula c7h17n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 004f72p8f4, chemically known as 2-((aminocarbonyl)oxy)-n,n,n-trimethyl-1-propanaminium but generally known as bethanechol, which bears us nih compound identifier 2370. european medicines agency schedules bethanechol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13063mig. world health organization schedules bethanechol in its anatomical therapeutic chemical (atc) classification. as of q4 2014, bethanechol remains the us fda preferred term for this commodity. bethanechol bears us nlm identifiers umls id c0053526 and nci concept code c76039. smiles: o(c(c[n](c)(c)c)c)c(=o)n.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pilocarpine. this classification denotes a cholinergic agonist with the molecular formula c11h16n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 01mi4q9di3, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)- but generally known as pilocarpine, which bears us nih compound identifier 5910. european medicines agency schedules pilocarpine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03818mig. world health organization schedules pilocarpine in its anatomical therapeutic chemical (atc) classification. most nations schedule pilocarpine under hs 29399990 and sitc 54149. as of q4 2014, pilocarpine remains the us fda preferred term for this commodity. pilocarpine bears us nlm identifiers umls id c0031923 and nci concept code c62068. smiles: ccc1c(coc1=o)cc2=cn=cn2c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tropatepine hydrochlorate. this classification denotes a tropane and dibenzothiepin with the molecular formula c22h23ns, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier c27hy5rfu5, chemically known as 8-azabicyclo(3.2.1)octane, 3-dibenzo(b,e)thiepin-11(6h)-ylidene-8-methyl- but generally known as tropatepine, which bears us nih compound identifier 72148. european medicines agency schedules tropatepine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11340mig. world health organization schedules tropatepine in its anatomical therapeutic chemical (atc) classification. tropatepine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tropatepine hydrochlorate under hs 29349990 and sitc 51579. smiles: s1c2c(c(=c3\\cc4n(c(cc4)c3)c)/c3c(c1)cccc3)cccc2.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. esterase inhibitor. this classification denotes a cholinergic agonist with the molecular formula c8h13no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4aln5933bh, chemically known as 1,2,5,6-tetrahydro-1-methylnicotinic acid, methyl ester but generally known as arecoline, which bears us nih compound identifier 2230. arecoline most often comes in base, bromide, hydrobromide, hydrochloride, iodomethylate, methiodide, and p-stibonobenzoic acid forms. smiles: cn1ccc=c(c1)c(=o)oc.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. ambenonium. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c28h42cl2n4o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier l16pun799n, chemically known as benzenemethanaminium, n,n-((1,2-dioxo-1,2-ethanediyl)bis(imino-2,1-ethanediyl))bis(2-chloro-n,n-diethyl- but generally known as ambenonium, which bears us nih compound identifier 2131. ambenonium most often comes in base, chloride, and dichloride forms. european medicines agency schedules ambenonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00425mig. world health organization schedules ambenonium in its anatomical therapeutic chemical (atc) classification. ambenonium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, ambenonium remains the us fda preferred term for this commodity. ambenonium bears us nlm identifiers umls id c0002412 and nci concept code c76136. smiles: clc1c(c[n](ccnc(=o)c(=o)ncc[n](cc2c(cl)cccc2)(cc)cc)(cc)cc)cccc1.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. galantamine. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c17h21no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0d3q044kca, chemically known as 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4as-(4a.alpha.,6.beta.,8ar*))- but generally known as galantamine, which bears us nih compound identifier 3449. european medicines agency schedules galantamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07870mig. the term galantamine is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules galantamine in its anatomical therapeutic chemical (atc) classification. galantamine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule galantamine under hs 29399900 and sitc 54149. as of q4 2014, galantamine remains the us fda preferred term for this commodity. galantamine bears us nlm identifiers umls id c0016967 and nci concept code c65797. smiles: o1c2c3(c4c1c(oc)ccc4cn(cc3)c)c=cc(o)c2.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. neostigmine. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c12h19n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3982twq96g, chemically known as 3-trimethylammoniumphenyl n,n-dimethylcarbamate but generally known as neostigmine, which bears us nih compound identifier 4456. european medicines agency schedules neostigmine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03411mig. world health organization schedules neostigmine in its anatomical therapeutic chemical (atc) classification. neostigmine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, neostigmine remains the us fda preferred term for this commodity. neostigmine bears us nlm identifiers umls id c0027679 and nci concept code c75024. smiles: cn(c)c(=o)oc1=cc=cc(=c1)[n+](c)(c)c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pyridostigmine. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c9h13n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 19qm69hh21, chemically known as pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) but generally known as pyridostigmine, which bears us nih compound identifier 4991. european medicines agency schedules pyridostigmine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub15059mig. world health organization schedules pyridostigmine in its anatomical therapeutic chemical (atc) classification. pyridostigmine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, pyridostigmine remains the us fda preferred term for this commodity. pyridostigmine bears us nlm identifiers umls id c0034261 and nci concept code c76139. smiles: o(c1c[n](ccc1)c)c(=o)n(c)c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tacrine. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c13h14n2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4vx7ynb537, chemically known as 1,2,3,4-tetrahydro-acridin-9-ylamine but generally known as tacrine, which bears us nih compound identifier 1935. european medicines agency schedules tacrine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10796mig. the term tacrine is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). world health organization schedules tacrine in its anatomical therapeutic chemical (atc) classification. tacrine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tacrine under hs 29339990 and sitc 51577. as of q4 2014, tacrine remains the us fda preferred term for this commodity. tacrine bears us nlm identifiers umls id c0039245 and nci concept code c61961. smiles: n1c2c(cccc2)c(n)c2c1cccc2.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cevimeline. this classification denotes a cholinergic agonist with the molecular formula c10h17nos, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k9v0cdq56e, chemically known as 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine but generally known as cevimeline, which bears us nih compound identifier 83898. european medicines agency schedules cevimeline in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07461mig. the term cevimeline is an international non-proprietary name. world health organization schedules cevimeline in its anatomical therapeutic chemical (atc) classification. cevimeline is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule cevimeline under hs 29349990 and sitc 51579. as of q4 2014, cevimeline remains the us fda preferred term for this commodity. cevimeline bears us nlm identifiers umls id c0093437 and nci concept code c66873. smiles: cc1oc2(cn3ccc2cc3)cs1.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. acetylcholine. this classification denotes a cholinergic agonist with the molecular formula c7h16no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n9yns0m02x, chemically known as 2-acetyloxy-n,n,n-trimethylethanaminium but generally known as acetylcholine, which bears us nih compound identifier 187. acetylcholine comes in many forms including base, bromhydrate, bromide, chloride, hydrobromide, hydrochloride, iodide, mustard, mustard aziridinium, and perchlorate. european medicines agency schedules acetylcholine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00261mig. world health organization schedules acetylcholine in its anatomical therapeutic chemical (atc) classification. acetylcholine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, acetylcholine remains the us fda preferred term for this commodity. acetylcholine bears us nlm identifiers umls id c0001041 and nci concept code c77840. smiles: o(cc[n](c)(c)c)c(=o)c. .. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. aclatonium napadisilate. this classification denotes a cholinergic agonist with the molecular formula 2c10h20no4.c10h6o6s2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier yx23434yhq, chemically known as 2-(2-(acetyloxy)-1-oxopropoxy)-n,n,n-trimethylethanaminium, 1,5-naphthalenedisulfonate (2:1) but generally known as aclatonium napadisilate, which bears us nih compound identifier 41315. european medicines agency schedules aclatonium napadisilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05244mig. the term aclatonium napadisilate is an international non-proprietary name or inn (see who inn reference publication, volume 34, no. 10 1980, list 20). most nations schedule aclatonium napadisilate under hs 29239000 and sitc 51481. as of q4 2014, aclatonium napadisilate remains the us fda preferred term for this commodity. aclatonium napadisilate bears us nlm identifiers umls id c0076758 and nci concept code c91037. smiles: cc(c(=o)occ[n+](c)(c)c)oc(=o)c.cc(c(=o)occ[n+](c)(c)c)oc(=o)c.c1=cc2=c(c=cc=c2s(=o)(=o)[o-])c(=c1)s(=o)(=o)[o-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. benzpyrinium. this classification denotes a cholinergic agonist with the molecular formula c15h17n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier p00dm5t7zs, chemically known as 1-benzyl-3-hydroxypyridinium dimethylcarbamate but generally known as benzpyrinium, which bears us nih compound identifier 11481. european medicines agency schedules benzpyrinium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05766mig. the term benzpyrinium is an international non-proprietary name. as of q4 2014, benzpyrinium remains the us fda preferred term for this commodity. benzpyrinium bears us nlm identifiers umls id c0599261 and nci concept code c87446. smiles: cn(c)c(=o)oc1=c[n+](=cc=c1)cc2=cc=cc=c2.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. hexafluorenium or hexafluronium. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c36h42n2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 55w5l6g81r, chemically known as 1,6-hexanediaminium, n, n-di-9h-fluoren-9-yl-n,n,n,n-tetramethyl-, dibromide but generally known as hexafluorenium, which bears us nih compound identifier 3601. hexafluorenium or hexafluronium bears us nlm identifiers umls id c0062619 and nci concept code c76138. smiles: c[n+](c)(cccccc[n+](c)(c)c1c2=cc=cc=c2c3=cc=cc=c13)c4c5=cc=cc=c5c6=cc=cc=c46.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. distigmine. this classification denotes a cholinesterase inhibitor with the molecular formula c22h32n4o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier t940307o7b, chemically known as 3,3-(1,6-hexanediylbis((methylimino)carbonyl)oxy)bis(1-methylpyridinium) dibromide but generally known as distigmine, which bears us nih compound identifier 27522. european medicines agency schedules distigmine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01797mig. world health organization schedules distigmine in its anatomical therapeutic chemical (atc) classification. distigmine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, distigmine remains the us fda preferred term for this commodity. smiles: br.br.o(c(=o)n(ccccccn(c)c(=o)oc1c[n](ccc1)c)c)c1c[n](ccc1)c. .. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. diisopropyl fluorophosphate or dyflos or fluostigmine or isoflurophate. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c6h14fo3p, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 12uhw9r67n, chemically known as phosphorofluoridic acid, diisopropyl ester but generally known as dyflos, which bears us nih compound identifier 5936. european medicines agency schedules isoflurophate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14274mig. smiles: cc(c)op(=o)(oc(c)c)f. smiles: cc(c)op(=o)(oc(c)c)f.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. furtrethonium iodide. this classification denotes a cholinergic agonist with the molecular formula c8h14no.i, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1d064nld7g, chemically known as 2-furanmethanaminium, n,n,n-trimethyl-, iodide (9ci) but generally known as furtrethonium iodide, which bears us nih compound identifier 10937. european medicines agency schedules furtrethonium iodide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07854mig. the term furtrethonium iodide is an international non-proprietary name. most nations schedule furtrethonium iodide under hs 29321900 and sitc 51569. as of q4 2014, furtrethonium iodide remains the us fda preferred term for this commodity. furtrethonium iodide bears us nlm identifiers umls id c0118398 and nci concept code c76041. smiles: i.o1c(c[n](c)(c)c)ccc1.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. zanapezil. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c25h32n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0a0800o89n, chemically known as 1-propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1h-1-benzazepin-8-yl)- but generally known as zanapezil, which bears us nih compound identifier 198752. the term zanapezil is an international non-proprietary name or inn (see who inn reference publication, volume 16., no. 1.2002, list 47). most nations schedule zanapezil under hs 29333999 and sitc 51574. as of q4 2014, zanapezil remains the us fda preferred term for this commodity. zanapezil bears us nlm identifiers umls id c1883595 and nci concept code c66683. smiles: c1ccnc2=c(c1)c=cc(=c2)c(=o)ccc3ccn(cc3)cc4=cc=cc=c4.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. metrifonate or trichlorfon. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c4h8cl3o4p, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier dbf2dg4g2k, chemically known as 1-hydroxy-2,2,2-trichloroethylphosphonic acid dimethyl ester but generally known as metrifonate, which bears us nih compound identifier 5853. european medicines agency schedules metrifonate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08919mig. the term metrifonate is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7). world health organization schedules metrifonate in its anatomical therapeutic chemical (atc) classification. metrifonate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. metrifonate or trichlorfon bears us nlm identifiers umls id c0040898 and nci concept code c84225. smiles: clc(cl)(cl)c(p(=o)(oc)oc)o.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. quilostigmine. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c23h27n3o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 2l1yno4sqj, chemically known as 2(1h)-isoquinolinecarboxylic acid, 3,4-dihydro-, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-yl ester, (3as-cis)- but generally known as quilostigmine, which bears us nih compound identifier 132228. european medicines agency schedules quilostigmine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10196mig. the term quilostigmine is an international non-proprietary name or inn (see who inn reference publication, volume 11, no. 3 1997, list 38). quilostigmine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule quilostigmine under hs 29334990 and sitc 51575. as of q4 2014, quilostigmine remains the us fda preferred term for this commodity. quilostigmine bears us nlm identifiers umls id c0755738 and nci concept code c81922. smiles: o(c1cc2c3(c(n(cc3)c)n(c2cc1)c)c)c(=o)n1ccc2c(c1)cccc2.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. rivastigmine. this classification denotes an acetylcholinesterase inhibitor, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier pki06m3iw0. european medicines agency schedules rivastigmine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10345mig. rivastigmine generally arises in the molecular formula c14h22n2o2. the term rivastigmine is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 1 1998, list 39.) rivastigmine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule rivastigmine under hs 29242995 and sitc 51479. as of q4 2014, rivastigmine remains the us fda preferred term for this commodity. rivastigmine bears us nlm identifiers umls id c0649350 and nci concept code c66519. smiles: o(c1cc(c(n(c)c)c)ccc1)c(=o)n(cc)c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. telenzepine. this classification denotes an antimuscarinic agent with the molecular formula c19h22n4o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0990eg3k10, chemically known as 4,9-dihydro-3-methyl-4-((4-methyl-1-piperazinyl)acetyl)-10h-thieno(3,4-b)(1,5)benzodiazepin-10-one but generally known as telenzepine, which bears us nih compound identifier 5387. european medicines agency schedules telenzepine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10871mig. the term telenzepine is an international non-proprietary name. telenzepine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule telenzepine under hs 29349990 and sitc 51579. as of q4 2014, telenzepine remains the us fda preferred term for this commodity. telenzepine bears us nlm identifiers umls id c0076066 and nci concept code c75285. smiles: s1c(c2n(c(=o)cn3ccn(cc3)c)c3c([nh]c(=o)c2c1)cccc3)c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. zifrosilone. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c11h13f3osi, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6275788o83, chemically known as 2,2,2-trifluoro-3-(trimethylsilyl)acetophenone but generally known as zifrosilone, which bears us nih compound identifier 60811. european medicines agency schedules zifrosilone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00154mig. the term zifrosilone is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35). zifrosilone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, zifrosilone remains the us fda preferred term for this commodity. zifrosilone bears us nlm identifiers umls id c0288321 and nci concept code c82222. smiles: c[si](c)(c)c1=cc=cc(=c1)c(=o)c(f)(f)f.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. aceclidine. this classification denotes a cholinergic agonist with the molecular formula c9h15no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0578k3elio, chemically known as 3-quinuclidinol, acetate (ester) but generally known as aceclidine, which bears us nih compound identifier 1979. aceclidine most often comes in forms base, hydrochloride, and salicylate. european medicines agency schedules aceclidine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05199mig. the term aceclidine is an international non-proprietary name. world health organization schedules aceclidine in its anatomical therapeutic chemical (atc) classification. aceclidine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule aceclidine under hs 29333999 and sitc 51574. as of q4 2014, aceclidine remains the us fda preferred term for this commodity. aceclidine bears us nlm identifiers umls id c0000948 and nci concept code c81044. smiles: o(c1c2ccn(c1)cc2)c(=o)c.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. aceclidine hydrochloride. this classification denotes the hydrochloride form of a cholinergic agonist with the molecular formula c9h15no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0578k3elio, chemically known as 3-quinuclidinol, acetate (ester) but more generally known as aceclidine, which bears us nih compound identifier 1979. aceclidine most often comes in forms base, hydrochloride, and salicylate. european medicines agency schedules aceclidine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05199mig. the term aceclidine is an international non-proprietary name. world health organization schedules aceclidine in its anatomical therapeutic chemical (atc) classification. aceclidine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations, for tariff and trade purposes, schedule aceclidine hydrochloride under hs 29333999 and sitc 51574. as of q4 2014, aceclidine hydrochloride remains us fdas preferred term for this commodity. aceclidine hydrochloride bears us nlm identifiers umls id c1529400 and nci concept code c96880. smiles: cc(=o)oc1cn2ccc1cc2.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. aceclidine salicylate. this classification denotes the salicylate form of a cholinergic agonist with the molecular formula c9h15no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0578k3elio, chemically known as 3-quinuclidinol, acetate (ester) but more generally known as aceclidine, which bears us nih compound identifier 1979. aceclidine most often comes in forms base, hydrochloride, and salicylate. european medicines agency schedules aceclidine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05199mig. the term aceclidine is an international non-proprietary name. world health organization schedules aceclidine in its anatomical therapeutic chemical (atc) classification. aceclidine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations, for tariff and trade purposes, schedule aceclidine salicylate under hs 29333999 and sitc 51574. as of q4 2014, aceclidine salicylate remains us fdas preferred term for this commodity. aceclidine salicylate bears us nlm identifiers umls id c3273097 and nci concept code c96882. smiles: cc(=o)oc1cn2ccc1cc2.c1ccc(c(c1)c(=o)o)o.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. acetylcholine chloride. this classification denotes a cholinergic agonist with the molecular formula c7h16no2.cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier af73293c2r, chemically known as 2-acetyloxy-n,n,n-trimethylethanaminium chloride but more generally known as acetylcholine chloride, which bears us nih compound identifier 6060. the base preparation, acetylcholine, also comes in forms base, bromide, hydrobromide, hydrochloride, iodide, mustard, mustard aziridinium, and perchlorate. european medicines agency schedules acetylcholine chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05228mig. the term acetylcholine chloride is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3). most nations, for tariff and trade purposes, schedule acetylcholine chloride under hs 29239000 and sitc 51481. as of q4 2014, acetylcholine chloride remains us fdas preferred term for this commodity. acetylcholine chloride bears us nlm identifiers umls id c0055389 and nci concept code c47382. smiles: cc(=o)occ[n+](c)(c)c.[cl-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. ambenonium chloride. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c28h42cl2n4o2.2cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 51fob87g3i, chemically known as n,n-bis(2-diethylaminoethyl)oxamide bis(2-chlorobenzyl chloride) but more generally known as ambenonium chloride, which bears us nih compound identifier 8288. european medicines agency schedules ambenonium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05394mig. the term ambenonium chloride is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3). most nations, for tariff and trade purposes, schedule ambenonium chloride under hs 29242995 and sitc 51479. as of q4 2014, ambenonium chloride remains us fdas preferred term for this commodity. ambenonium chloride bears us nlm identifiers umls id c1448379 and nci concept code c47388. smiles: cc[n+](cc)(ccnc(=o)c(=o)ncc[n+](cc)(cc)cc1ccccc1cl)cc2ccccc2cl.[cl-].[cl-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. benzpyrinium bromide. this classification denotes a cholinergic agonist with the molecular formula c15h17n2o2.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier x0l78yb79m, chemically known as pyridinium, 3-((dimethylaminocarbonyl)oxy)-1-(phenylmethyl)-, bromide but more generally known as benzpyrinium bromide, which bears us nih compound identifier 11481. european medicines agency schedules benzpyrinium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05766mig. the term benzpyrinium bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule benzpyrinium bromide under hs 29333999 and sitc 51574. as of q4 2014, benzpyrinium bromide remains us fdas preferred term for this commodity. benzpyrinium bromide bears us nlm identifiers umls id c2698369 and nci concept code c76611. smiles: cn(c)c(=o)oc1ccc[n+](c1)cc2ccccc2.[br-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cevimeline hydrochloride. this classification denotes a cholinergic agonist, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier p81q6v85np. european medicines agency schedules cevimeline hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01186mig. cevimeline hydrochloride generally arises in the molecular formula 2c10h17nos.2clh.h2o. the term cevimeline hydrochloride is a united states adopted name designation. most nations, for tariff and trade purposes, schedule cevimeline hydrochloride under hs 29349990 and sitc 51579. as of q4 2014, cevimeline hydrochloride remains us fdas preferred term for this commodity. cevimeline hydrochloride bears us nlm identifiers umls id c0874063 and nci concept code c1337. smiles: c[c@h]1o[c@@]2(cn3ccc2cc3)cs1.c[c@h]1o[c@@]2(cn3ccc2cc3)cs1.o.cl.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cevimeline hydrochloride hemihydrate. this classification denotes a cholinergic agonist with the molecular formula 2c10h17nos.2clh.h2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier p81q6v85np, chemically known as (+/-)-cis-2-methylspiro(1,3-oxathiolane-5,3-quinuclidine)hydrochloride, hemihydrate, but more generally known as cevimeline hydrochloride hemihydrate, which bears us nih compound identifier 83927. european medicines agency schedules cevimeline hydrochloride hemihydrate or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07461mig. most nations, for tariff purposes, schedule cevimeline hydrochloride hemihydrate under hs 29349990. smiles: c[c@h]1o[c@@]2(cn3ccc2cc3)cs1.c[c@h]1o[c@@]2(cn3ccc2cc3)cs1.o.cl.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. distigmine bromide. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c22h32n4o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 750f36op6j, chemically known as 3,3-(1,6-hexanediylbis((methylimino)carbonyl)oxy)bis(1-methylpyridinium) dibromide but more generally known as distigmine bromide, which bears us nih compound identifier 27522. european medicines agency schedules distigmine bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06323mig. the term distigmine bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 21 no. 12 1967, list 7). most nations, for tariff and trade purposes, schedule distigmine bromide under hs 29333999 and sitc 51574. as of q4 2014, distigmine bromide remains us fdas preferred term for this commodity. distigmine bromide bears us nlm identifiers umls id c0012757 and nci concept code c87487. smiles: c[n+]1cccc(c1)oc(=o)n(c)ccccccn(c)c(=o)oc2ccc[n+](c2)c.[br-].[br-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. galantamine hydrobromide. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c17h21no3.brh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier mj4ptd2vvw, chemically known as 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-benzofuro(4,3,2-efg)(2)benzazocin-6-ol hbr but more generally known as galantamine hydrobromide, which bears us nih compound identifier 121587. european medicines agency schedules galantamine hydrobromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02301mig. most nations, for tariff and trade purposes, schedule galantamine hydrobromide under hs 29399900 and sitc 54149. as of q4 2014, galantamine hydrobromide remains us fdas preferred term for this commodity. galantamine hydrobromide bears us nlm identifiers umls id c0949312 and nci concept code c47546. smiles: cn1cc[c@@]23c=c[c@@h](c[c@@h]2oc4c3c(ccc4oc)c1)o.br.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. hexafluronium bromide. this classification denotes an antispasmotic agent with the molecular formula c36h42n2.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier b64njg83k2, chemically known as 1,6-hexanediaminium, n, n-di-9h-fluoren-9-yl-n,n,n,n-tetramethyl-, dibromide but more generally known as hexafluorenium bromide, which bears us nih compound identifier 3601. european medicines agency schedules hexafluronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14099mig. the term hexafluronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 19 1975, list 5). world health organization schedules hexafluorenium bromide in its anatomical therapeutic chemical (atc) classification. most nations, for tariff and trade purposes, schedule hexafluronium bromide under hs 29239000. smiles: c[n+](c)(cccccc[n+](c)(c)c1c2ccccc2-c3c1cccc3)c4c5ccccc5-c6c4cccc6.[br-].[br-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. neostigmine bromide. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c12h19n2o2.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 005syp50g5, chemically known as carbamic acid, dimethyl-, ester with (m-hydroxyphenyl)trimethylammonium bromide but more generally known as neostigmine bromide, which bears us nih compound identifier 8246. european medicines agency schedules neostigmine bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09195mig. the term neostigmine bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule neostigmine bromide under hs 29242995 and sitc 51479. as of q4 2014, neostigmine bromide remains us fdas preferred term for this commodity. neostigmine bromide bears us nlm identifiers umls id c0282261 and nci concept code c76612. smiles: cn(c)c(=o)oc1cccc(c1)[n+](c)(c)c.[br-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pilocarpine hydrochloride. this classification denotes a cholinergic agonist with the molecular formula c11h16n2o2.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0ww6d218xj, chemically known as 3-isopilocarpine, monohydrochloride but more generally known as pilocarpine hydrochloride, which bears us nih compound identifier 4819. european medicines agency schedules pilocarpine hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14870mig. most nations, for tariff and trade purposes, schedule pilocarpine hydrochloride under hs 29399990 and sitc 54149. as of q4 2014, pilocarpine hydrochloride remains us fdas preferred term for this commodity. pilocarpine hydrochloride bears us nlm identifiers umls id c0770456 and nci concept code c748. smiles: cc[c@h]1[c@h](coc1=o)cc2cncn2c.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pilocarpine monohydrochloride. this classification denotes a cholinergic agonist with the molecular formula c11h16n2o2.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0ww6d218xj, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, monohydrochloride, (3s,4r)-, but more generally known as pilocarpine monohydrochloride, which bears us nih compound identifier 4819. european medicines agency schedules pilocarpine monohydrochloride or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03818mig. most nations, for tariff purposes, schedule pilocarpine monohydrochloride under hs 29399990. smiles: cc[c@h]1[c@h](coc1=o)cc2cncn2c.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pilocarpine mononitrate. this classification denotes a cholinergic agonist with the molecular formula c11h16n2o2.hno3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m20t465h6j, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)-, mononitrate, but more generally known as pilocarpine mononitrate, which bears us nih compound identifier 83930. european medicines agency schedules pilocarpine mononitrate or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03818mig. most nations, for tariff purposes, schedule pilocarpine mononitrate under hs 29399990. smiles: cc[c@h]1[c@h](coc1=o)cc2cncn2c.[n+](=o)(o)[o-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pilocarpine nitrate. this classification denotes a cholinergic agonist with the molecular formula c11h16n2o2.hno3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m20t465h6j, chemically known as 2(3h)-furanone, 3-ethyldihydro-4-((1-methyl-1h-imidazol-5-yl)methyl)-, (3s-cis)-, mononitrate but more generally known as pilocarpine nitrate, which bears us nih compound identifier 83930. european medicines agency schedules pilocarpine nitrate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03821mig. most nations, for tariff and trade purposes, schedule pilocarpine nitrate under hs 29399990 and sitc 54149. as of q4 2014, pilocarpine nitrate remains us fdas preferred term for this commodity. pilocarpine nitrate bears us nlm identifiers umls id c0351975 and nci concept code c91038. smiles: cc[c@h]1[c@h](coc1=o)cc2cncn2c.[n+](=o)(o)[o-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pyridostigmine bromide. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c9h13n2o2.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier kvi301na53, chemically known as pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester) but more generally known as pyridostigmine bromide, which bears us nih compound identifier 4991. european medicines agency schedules pyridostigmine bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10167mig. the term pyridostigmine bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule pyridostigmine bromide under hs 29333910 and sitc 51574. as of q4 2014, pyridostigmine bromide remains us fdas preferred term for this commodity. pyridostigmine bromide bears us nlm identifiers umls id c0034262 and nci concept code c47697. smiles: c[n+]1cccc(c1)oc(=o)n(c)c.[br-].. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. rivastigmine hydrogen tartrate. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c14h22n2o2.c4h6o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9iy2357jpe, chemically known as 2,6-dioxo-4-phenyl-piperidine-3-carbonitrile but more generally known as rivastigmine hydrogen tartrate, which bears us nih compound identifier 77991. european medicines agency schedules rivastigmine hydrogen tartrate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04257mig. most nations, for tariff and trade purposes, schedule rivastigmine hydrogen tartrate under hs 29242995 and sitc 51479. smiles: ccn(c)c(=o)oc1cccc(c1)[c@h](c)n(c)c.[c@@h]([c@h](c(=o)o)o)(c(=o)o)o.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. rivastigmine hydrogentartrate. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c14h22n2o2.c4h6o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9iy2357jpe, chemically known as carbamic acid, n-ethyl-n-methyl-, 3-((1s)-1-(dimethylamino)ethyl)phenyl ester, (2r,3r)-2,3-dihydroxybutanedioate (1:1), but more generally known as rivastigmine hydrogentartrate, which bears us nih compound identifier 77990. european medicines agency schedules rivastigmine hydrogentartrate or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10345mig. most nations, for tariff purposes, schedule rivastigmine hydrogentartrate under hs 29242995. smiles: ccn(c)c(=o)oc1cccc(c1)[c@h](c)n(c)c.[c@@h]([c@h](c(=o)o)o)(c(=o)o)o.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tacrine hydrochloride. this classification denotes an acetylcholinesterase inhibitor, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4966rng0bu. european medicines agency schedules tacrine hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04665mig. tacrine hydrochloride generally arises in the molecular formula c13h15cln2. the term tacrine hydrochloride is a united states adopted name designation. most nations, for tariff and trade purposes, schedule tacrine hydrochloride under hs 29339990 and sitc 51577. as of q4 2014, tacrine hydrochloride remains us fdas preferred term for this commodity. tacrine hydrochloride bears us nlm identifiers umls id c0699954 and nci concept code c47742. smiles: c1ccc2c(c1)c(c3c(n2)cccc3)n.cl.. "
"cholinergic drugs and cholinesterase inhibitors. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. ipidacrine. this classification denotes an anticholinergic agent with the molecular structure c12h16n2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier, cv71vtp0vn chemically known as 9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinoline, but more commonly known as ipidacrine, which bears u.s. nih compound identifier 604519. european medicines agency schedules ipidacrine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08273mig. the term ipidacrine is an international non-proprietary name or inn (see world health organization inn reference publication, volume 10, no. 3, 1996, list 36).. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. . "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. benztropine or benzatropine. this classification denotes an antimuscarinic agent with the molecular formula c21h25no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1nhl2j4x8k, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo- (9ci) but generally known as benzatropine, which bears us nih compound identifier 6832. benzatropine most often comes in base and methanesulfonate forms. european medicines agency schedules benzatropine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05742mig. the term benzatropine is an international non-proprietary name. world health organization schedules benzatropine in its anatomical therapeutic chemical (atc) classification. benzatropine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, benztropine remains the us fda preferred term for this commodity. benztropine bears us nlm identifiers umls id c0005098 and nci concept code c61649. smiles: o(c1cc2n(c(cc2)c1)c)c(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. procyclidine. this classification denotes an antimuscarinic agent with the molecular formula c19h29no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier c6qe1q1tkr, chemically known as 1-pyrrolidinepropanol, alpha-cyclohexyl-alpha-phenyl- but generally known as procyclidine, which bears us nih compound identifier 4919. european medicines agency schedules procyclidine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10064mig. the term procyclidine is an international non-proprietary name. world health organization schedules procyclidine in its anatomical therapeutic chemical (atc) classification. procyclidine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule procyclidine under hs 29339990 and sitc 51577. as of q4 2014, procyclidine remains the us fda preferred term for this commodity. procyclidine bears us nlm identifiers umls id c0033254 and nci concept code c73270. smiles: oc(c1ccccc1)(ccn1cccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. trihexyphenidyl. this classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula c20h31no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6rc5v8b7po, chemically known as 1-piperidinepropanol, alpha-cyclohexyl-alpha-phenyl- but generally known as trihexyphenidyl, which bears us nih compound identifier 5572. european medicines agency schedules trihexyphenidyl in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11295mig. the term trihexyphenidyl is an international non-proprietary name. world health organization schedules trihexyphenidyl in its anatomical therapeutic chemical (atc) classification. trihexyphenidyl is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule trihexyphenidyl under hs 29333999 and sitc 51574. as of q4 2014, trihexyphenidyl remains the us fda preferred term for this commodity. trihexyphenidyl bears us nlm identifiers umls id c0041009 and nci concept code c61988. smiles: oc(c1ccccc1)(ccn1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tropicamide. this classification denotes a diagnostic reagent and antimuscarinic agent with the molecular formula c17h20n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n0a3z5xtc6, chemically known as hydracrylamide, n-ethyl-2-phenyl-n-(4-pyridylmethyl)- but generally known as tropicamide, which bears us nih compound identifier 5593. european medicines agency schedules tropicamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11342mig. the term tropicamide is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules tropicamide in its anatomical therapeutic chemical (atc) classification. tropicamide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tropicamide under hs 29333999 and sitc 51574. as of q4 2014, tropicamide remains the us fda preferred term for this commodity. tropicamide bears us nlm identifiers umls id c0041190 and nci concept code c47776. smiles: o=c(n(cc1ccncc1)cc)c(c1ccccc1)co.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. clidinium. this classification denotes an antimuscarinic agent with the molecular formula c22h26no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier bo76jf850n, chemically known as 1-azoniabicyclo(2.2.2)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl- but generally known as clidinium, which bears us nih compound identifier 2784. european medicines agency schedules clidinium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13391mig. clidinium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, clidinium remains the us fda preferred term for this commodity. clidinium bears us nlm identifiers umls id c0055877 and nci concept code c73138. smiles: o(c1c2cc[n](c1)(cc2)c)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. dicyclomine or dicycloverine. this classification denotes an antimuscarinic agent with the molecular formula c19h35no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 4kv4x8if6v, chemically known as cyclohexanecarboxylic acid, 1-cyclohexyl-, 2-(diethylamino)ethyl ester but more generally known as dicyclomine, which bears us nih compound identifier 3042. european medicines agency schedules dicycloverine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07103mig. the term dicycloverine is an international non-proprietary name or inn (see world health organization inn reference publication, volume 13, no. 12, 1959, list 3). world health organization schedules dicyclomine in its anatomical therapeutic chemical (atc) classification. dicyclomine bears us nlm identifiers umls id c0012125 and nci concept code c61720. smiles: ccn(cc)ccoc(=o)c1(ccccc1)c2ccccc2.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. propantheline. this classification denotes an antimuscarinic agent with the molecular formula c23h30no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1306v2b0q8, chemically known as 2-propanaminium, n-methyl-n-(1-methylethyl)-n-(2-((9h-xanthen-9-ylcarbonyl)oxy)ethyl)- but generally known as propantheline, which bears us nih compound identifier 4934. european medicines agency schedules propantheline in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04081mig. world health organization schedules propantheline in its anatomical therapeutic chemical (atc) classification. propantheline is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, propantheline remains the us fda preferred term for this commodity. propantheline bears us nlm identifiers umls id c0033447 and nci concept code c78077. smiles: o(cc[n](c(c)c)(c(c)c)c)c(=o)c1c2c(oc3c1cccc3)cccc2.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. glycopyrrolate. this classification denotes an antimuscarinic agent with the molecular formula c19h28no3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier a14fb57v1d, chemically known as 3-hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate but more generally known as glycopyrrolate, which bears u.s. national institutes of health compound identifier 3494. the european medicines agency schedules glycopyrronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02381mig. the term glycopyrronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 19 1975, list 5). the world health organization schedules glycopyrrolate in its anatomical therapeutic chemical (atc) classification. smiles: c[n+]1(ccc(c1)oc(=o)c(c2cccc2)(c3=cc=cc=c3)o)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. hyoscyamine. this classification denotes an antimuscarinic agent with the molecular formula c17h23no3, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier px44xo846x, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but more generally known as hyoscyamine, which bears u.s. national institutes of health compound identifier 3661. european medicines agency schedules hyoscyamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14160mig. world health organization schedules hyoscyamine in its anatomical therapeutic chemical (atc) classification and its who-dd or drug dictionary.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. homatropine hydrobromide. this classification denotes an antimuscarinic agent with the molecular formula c16h21no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 8qs6wcl55z, chemically known as 1-alpha-h,5-alpha-h-tropan-3-alpha-ol, mandelate (ester) but generally known as homatropine, which bears us nih compound identifier 3623. european medicines agency schedules homatropine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02529mig. world health organization schedules homatropine in its anatomical therapeutic chemical (atc) classification. most nations schedule homatropine hydrobromide under hs 29399990 and sitc 54149. as of q4 2014, homatropine hydrobromide remains the us fda preferred term for this commodity. homatropine hydrobromide bears us nlm identifiers umls id c0770458 and nci concept code c29093. smiles: o(c1cc2n(c(cc2)c1)c)c(=o)c(o)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. atropine. this classification denotes an antimuscarinic agent with the molecular formula c17h23no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7c0697dr9i, chemically known as 1alphah,5alphah-tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate but generally known as atropine, which bears us nih compound identifier 3661. atropine comes in many forms, including acetylsalicylic acidhydrobromide, hydrochloride, iodomethylate, isopropyl bromide, methobromide, methonitrate, methylbromide, methyl nitrate, metonitrate, nitrate, n-octyl bromide, n-oxide, n-oxide hydrochloride, octabromide, oxide, oxide hydrochloride, propionate ester, salicylate, and sulfate. european medicines agency schedules atropine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00621mig. world health organization schedules atropine in its anatomical therapeutic chemical (atc) classification. atropine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule atropine under hs 29399990 and sitc 54149. as of q4 2014, atropine remains the us fda preferred term for this commodity. atropine bears us nlm identifiers umls id c0004259 and nci concept code c28840. smiles: o(c1cc2n(c(cc2)c1)c)c(=o)c(c1ccccc1)co.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. biperiden. this classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula c21h29no.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k35n76cuhf, chemically known as 5-norbornene-2-methanol, alpha-phenyl-alpha-(2-piperidinoethyl)- but generally known as biperiden hydrochloride, which bears us nih compound identifier 2381. european medicines agency schedules biperiden hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00807mig. most nations schedule biperiden under hs 29333999 and sitc 51574. as of q4 2014, biperiden remains the us fda preferred term for this commodity. biperiden bears us nlm identifiers umls id c0005578 and nci concept code c65263. smiles: oc(c1c2cc(c1)c=c2)(ccn1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. ambutonium. this classification denotes an antimuscarinic agent with the molecular formula c20h27n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 4o677eq77u, chemically known as 4-dimethylamino-2,2-diphenylbutyramide but generally known as ambutonium, which bears us nih compound identifier 8276. european medicines agency schedules ambutonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12844mig. as of q4 2014, ambutonium remains the us fda preferred term for this commodity. ambutonium bears us nlm identifiers umls id c0301368 and nci concept code c79895. smiles: cc[n+](c)(c)ccc(c1=cc=cc=c1)(c2=cc=cc=c2)c(=o)n.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. anisotropine. this classification denotes an antimuscarinic agent with the molecular formula c16h29no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier mjj5g1g8om. as of q4 2014, anisotropine remains the us fda preferred term for this commodity. anisotropine bears us nlm identifiers umls id c0301369 and nci concept code c87426. smiles: cccc(ccc)c(=o)oc1cc2ccc(c1)[n+]2(c)c.[br-]. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. benactyzine. this classification denotes an anticholinergic agent with the molecular formula c20h25no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 595eg71r3f, chemically known as ethanol, 2-(diethylamino)-, benzilate hydrochloride but generally known as benactyzine, which bears us nih compound identifier 9330. benactyzine most often comes in base, chloride, hydrochloride, or methyl bromide forms. european medicines agency schedules benactyzine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05696mig. the term benactyzine is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3). benactyzine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule benactyzine under hs 29221980 and sitc 51461. as of q4 2014, benactyzine remains the us fda preferred term for this commodity. benactyzine bears us nlm identifiers umls id c0004962 and nci concept code c81454. smiles: o(ccn(cc)cc)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. benzilone or benzilonium. this classification denotes an antimuscarinic agent with the molecular formula c22h28no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier gy56lqx77b, chemically known as 1,1-diethyl-3-hydroxypyrrolidinium bromide benzilate but generally known as benzilone, which bears us nih compound identifier 66247. european medicines agency schedules benzilonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00722mig. world health organization schedules benzilone in its anatomical therapeutic chemical (atc) classification. benzilone or benzilonium bears us nlm identifiers umls id c2828307 and nci concept code c87444. smiles: cc[n+]1(ccc(c1)oc(=o)c(c2=cc=cc=c2)(c3=cc=cc=c3)o)cc.[br-].. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. bevonium. this classification denotes an anticholinergic agent with the molecular formula c22h28no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 34b0471e08, chemically known as 2-(hydroxymethyl)-n,n-dimethylpiperidinium methyl sulfate benzilate but generally known as bevonium, which bears us nih compound identifier 31800. bevonium most often comes in base and methyl sulfate forms, also called methylsulfate, methylsulphate, or even metilsulfate. european medicines agency schedules bevonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00794mig. world health organization schedules bevonium in its anatomical therapeutic chemical (atc) classification. bevonium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, bevonium remains the us fda preferred term for this commodity. bevonium bears us nlm identifiers umls id c0053533 and nci concept code c73804. smiles: o(cc1[n](cccc1)(c)c)c(=o)c(o)(c1ccccc1)c1ccccc1. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. bornaprine. this classification denotes an antimuscarinic agent with the molecular formula c21h31no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9m363fga7j, chemically known as 2-phenylbicyclo(2.2.1)heptane-2-carboxylic acid, 3-(diethylamino)propyl ester but generally known as bornaprine, which bears us nih compound identifier 30160. european medicines agency schedules bornaprine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05874mig. the term bornaprine is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16). world health organization schedules bornaprine in its anatomical therapeutic chemical (atc) classification. bornaprine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule bornaprine under hs 29221980 and sitc 51461. as of q4 2014, bornaprine remains the us fda preferred term for this commodity. bornaprine bears us nlm identifiers umls id c0053947 and nci concept code c90742. smiles: o(c(=o)c1(c2cc(c1)cc2)c1ccccc1)cccn(cc)cc.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. butinoline. this classification denotes an antimuscarinic agent with the molecular formula c20h21no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier g216926e9t, chemically known as 1,1-diphenyl-4-pyrrolidino-1-yl but-2-yn-1-ol but generally known as butinoline, which bears us nih compound identifier 68943. european medicines agency schedules butinoline in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06020mig. the term butinoline is an international non-proprietary name. butinoline is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule butinoline under hs 29339990 and sitc 51577. as of q4 2014, butinoline remains the us fda preferred term for this commodity. butinoline bears us nlm identifiers umls id c0772190 and nci concept code c78064. smiles: oc(c1ccccc1)(c1ccccc1)c#ccn1cccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. butylscopolamine. this classification denotes an antimuscarinic agent with the molecular formula c21h30no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 2z3e1of81v, chemically known as 3-oxa-9-azonitricyclo(3.3.1.0(2,4))nonane, 9-butyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, (7(s)-(1alpha,2beta,4beta,5alpha,7beta))- but generally known as butylscopolamine, which bears us nih compound identifier 160883. butylscopolamine most often comes in base and bromide forms. european medicines agency schedules butylscopolamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub20624. world health organization schedules butylscopolamine in its anatomical therapeutic chemical (atc) classification. as of q4 2014, butylscopolamine remains the us fda preferred term for this commodity. butylscopolamine bears us nlm identifiers umls id c2827093 and nci concept code c83571. smiles: o1c2c3[n](c(c12)cc(oc(=o)c(co)c1ccccc1)c3)(cccc)c. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. camylofin. this classification denotes a parasympatholytic with the molecular formula c19h32n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 340b6q764v, chemically known as phenyldiethylaminoethyl-1-aminoacetic acid, isopentyl ester but generally known as camylofin, which bears us nih compound identifier 5902. camylofin most often comes in base and hydrochloride forms. european medicines agency schedules camylofin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06068mig. world health organization schedules camylofin in its anatomical therapeutic chemical (atc) classification. camylofin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule camylofin under hs 29224995 and sitc 51465. as of q4 2014, camylofin remains the us fda preferred term for this commodity. smiles: o(ccc(c)c)c(=o)c(nccn(cc)cc)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. chlorbenzoxamine. this classification denotes an antimuscarinic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n52918slyn. european medicines agency schedules chlorbenzoxamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06176mig. chlorbenzoxamine generally arises in the molecular formula c27h31cln2o. the term chlorbenzoxamine is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4.) chlorbenzoxamine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule chlorbenzoxamine under hs 29335995 and sitc 51576. as of q4 2014, chlorbenzoxamine remains the us fda preferred term for this commodity. chlorbenzoxamine bears us nlm identifiers umls id c2699179 and nci concept code c79940. smiles: clc1c(c(occn2ccn(cc2)cc2c(cccc2)c)c2ccccc2)cccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cimetropium. this classification denotes an anticholinergic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1n3h74aytk, chemically known as (7(s)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.))-9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-3-oxa-9-azoniatricyclo(3.3.1.0(sup 2,4))nonane but generally known as cimetropium, which bears us nih compound identifier 6917944. european medicines agency schedules cimetropium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01298mig. the term cimetropium is an international non-proprietary name or inn (see who inn reference publication, volume 38, no. 6, 1984, list 24.) as of q4 2014, cimetropium remains the us fda preferred term for this commodity. smiles: none.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cycrimine. this classification denotes an antiparkinsonian agent and antimuscarinic agent with the molecular formula c19h29no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 543567rfqq, chemically known as 1-piperidinepropanol, .alpha.-cyclopentyl-.alpha.-phenyl-, hydrochloride but generally known as cycrimine, which bears us nih compound identifier 2911. european medicines agency schedules cycrimine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06867mig. the term cycrimine is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3). cycrimine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule cycrimine under hs 29333999 and sitc 51574. as of q4 2014, cycrimine remains the us fda preferred term for this commodity. cycrimine bears us nlm identifiers umls id c0056835 and nci concept code c65359. smiles: oc(c1cccc1)(ccn1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. deptropine or dibenzheptropine. this classification denotes a tropane with the molecular formula c23h27no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ay31301gkg, chemically known as 8-azabicyclo(3.2.1)octane, 3-((10,11-dihydro-5h-dibenzo(a,d)cyclohepten-5-yl)oxy)-8-methyl-, endo- but generally known as deptropine, which bears us nih compound identifier 16576. european medicines agency schedules deptropine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06984mig. world health organization schedules deptropine in its anatomical therapeutic chemical (atc) classification. deptropine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. smiles: o(c1cc2n(c(cc2)c1)c)c1c2c(ccc3c1cccc3)cccc2.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. dexetimide. this classification denotes an antimuscarinic agent with the molecular formula c23h26n2o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 43477qyx3d, chemically known as (rs)-3-(1-benzyl-4-piperidyl)-3-phenyl-2,6-piperidindion but generally known as dexetimide, which bears us nih compound identifier 21847. european medicines agency schedules dexetimide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07026mig. the term dexetimide is an international non-proprietary name or inn (see who inn reference publication, volume 25 , no. 10 1971, list 11). world health organization schedules dexetimide in its anatomical therapeutic chemical (atc) classification. dexetimide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule dexetimide under hs 29333999 and sitc 51574. as of q4 2014, dexetimide remains the us fda preferred term for this commodity. dexetimide bears us nlm identifiers umls id c0011785 and nci concept code c78069. smiles: o=c1nc(=o)ccc1(c1ccn(cc1)cc1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. difemerine. this classification denotes an antimuscarinic agent with the molecular formula c20h25no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 843c4upz2f, chemically known as benzeneacetic acid, alpha-hydroxy-alpha-phenyl-, 2-(dimethylamino)-2-methylpropyl ester but generally known as difemerine, which bears us nih compound identifier 165124. european medicines agency schedules difemerine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07117mig. the term difemerine is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7). world health organization schedules difemerine in its anatomical therapeutic chemical (atc) classification. difemerine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule difemerine under hs 29221980 and sitc 51461. as of q4 2014, difemerine remains the us fda preferred term for this commodity. difemerine bears us nlm identifiers umls id c0612470 and nci concept code c83670. smiles: o(cc(n(c)c)(c)c)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. dihexyverine. this classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula c20h35no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j2fq66ru9w, chemically known as 2-piperidinoethyl (1,1-bicyclohexyl)-1-carboxylate but generally known as dihexyverine, which bears us nih compound identifier 21788. european medicines agency schedules dihexyverine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07136mig. most nations schedule dihexyverine under hs 29333999 and sitc 51574. as of q4 2014, dihexyverine remains the us fda preferred term for this commodity. dihexyverine bears us nlm identifiers umls id c0771461 and nci concept code c97978. smiles: c1ccc(cc1)c2(ccccc2)c(=o)occn3ccccc3.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. diphemanil. this classification denotes an antimuscarinic agent with the molecular formula c20h24n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier q26tx1ud0w, chemically known as 4-(diphenylmethylene)-1,1-dimethylpiperidinium methylsulfate but generally known as diphemanil, which bears us nih compound identifier 6126. world health organization schedules diphemanil in its anatomical therapeutic chemical (atc) classification. diphemanil is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, diphemanil remains the us fda preferred term for this commodity. diphemanil bears us nlm identifiers umls id c0301371 and nci concept code c78071. smiles: c[n+]1(ccc(=c(c2=cc=cc=c2)c3=cc=cc=c3)cc1)c.cos(=o)(=o)[o-]. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. gallamine. this classification denotes an anticholinergic agent with the molecular formula c24h45n3o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1146x1wtnm, chemically known as 1,2,3-trihydroxybenzene but generally known as gallamine, which bears us nih compound identifier 1057. european medicines agency schedules gallamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02305mig. world health organization schedules gallamine in its anatomical therapeutic chemical (atc) classification. gallamine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, gallamine remains the us fda preferred term for this commodity. gallamine bears us nlm identifiers umls id c0016971 and nci concept code c87604. smiles: oc1c(o)cccc1o. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. edrophonium chloride. this classification denotes an acetylcholinesterase inhibitor with the molecular formula c10h16no.cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier qo611ksm5p, chemically known as benzenaminium, n-ethyl-3-hydroxy-n,n-dimethyl- but generally known as edrophonium chloride, which bears us nih compound identifier 3202. european medicines agency schedules edrophonium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06461mig. the term edrophonium chloride is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3). most nations schedule edrophonium chloride under hs 29239000 and sitc 51481. as of q4 2014, edrophonium chloride remains the us fda preferred term for this commodity. edrophonium chloride bears us nlm identifiers umls id c0013617 and nci concept code c47507. smiles: cc[n+](c)(c)c1=cc(=cc=c1)o.[cl-].. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. elantrine. this classification denotes an anticholinergic agent with the molecular formula c20h24n2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier mv4fo7v23v, chemically known as rmi 80,029 but generally known as elantrine, which bears us nih compound identifier 5383521. european medicines agency schedules elantrine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06476mig. the term elantrine is an international non-proprietary name. elantrine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule elantrine under hs 29339930 and sitc 51577. as of q4 2014, elantrine remains the us fda preferred term for this commodity. elantrine bears us nlm identifiers umls id c2825643 and nci concept code c81459. smiles: n1(cc2c(/c(=c\\ccn(c)c)c3c1cccc3)cccc2)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. emepronium. this classification denotes a muscarinic antagonist and parasympatholytic with the molecular formula c20h28n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 04qq8swa4u, chemically known as benzenepropanaminium, n-ethyl-n,n,alpha-trimethyl-gamma-phenyl- but generally known as emepronium, which bears us nih compound identifier 34055. european medicines agency schedules emepronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01875mig. world health organization schedules emepronium in its anatomical therapeutic chemical (atc) classification. emepronium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, emepronium remains the us fda preferred term for this commodity. smiles: [n](c(cc(c1ccccc1)c1ccccc1)c)(cc)(c)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. ethybenztropin or ethybenztropine or tropethydrylin. this classification denotes an anticholinergic agent with the molecular formula c22h27no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier g1x2x9n95n, chemically known as 8-azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-ethyl-, endo- but generally known as ethybenztropine, which bears us nih compound identifier 71637. european medicines agency schedules etybenzatropine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07348mig. the term etybenzatropine is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules ethybenztropine in its anatomical therapeutic chemical (atc) classification. smiles: ccn1c2ccc1cc(c2)oc(c3=cc=cc=c3)c4=cc=cc=c4.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. fenpiverinium. this classification denotes an antimuscarinic agent with the molecular formula c22h29n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier kp2l8lc73b. european medicines agency schedules fenpiverinium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02124mig. fenpiverinium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, fenpiverinium remains the us fda preferred term for this commodity. fenpiverinium bears us nlm identifiers umls id c0060190 and nci concept code c87638. smiles: c[n+]1(ccccc1)ccc(c2=cc=cc=c2)(c3=cc=cc=c3)c(=o)n.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. fentonium. this classification denotes an antimuscarinic agent with the molecular formula c31h34no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 26bf4s8fo5. european medicines agency schedules fentonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02132mig. fentonium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, fentonium remains the us fda preferred term for this commodity. fentonium bears us nlm identifiers umls id c0060206 and nci concept code c83712. smiles: c[n+]1(c2ccc1cc(c2)oc(=o)c(co)c3=cc=cc=c3)cc(=o)c4=cc=c(c=c4)c5=cc=cc=c5.[br-].. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. flavoxate. this classification denotes an antimuscarinic agent with the molecular formula c24h25no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3e74y80mey, chemically known as 4h-1-benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-piperidinoethyl ester, hydrochloride but generally known as flavoxate, which bears us nih compound identifier 3354. european medicines agency schedules flavoxate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07635mig. the term flavoxate is an international non-proprietary name. world health organization schedules flavoxate in its anatomical therapeutic chemical (atc) classification. flavoxate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule flavoxate under hs 29349990 and sitc 51579. as of q4 2014, flavoxate remains the us fda preferred term for this commodity. flavoxate bears us nlm identifiers umls id c0016225 and nci concept code c61765. smiles: o(ccn1ccccc1)c(=o)c1c2oc(c(c(=o)c2ccc1)c)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. hexocyclium. this classification denotes an antimuscarinic agent with the molecular formula c20h33n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ll3147pi1t. european medicines agency schedules hexocyclium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02515mig. hexocyclium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, hexocyclium remains the us fda preferred term for this commodity. hexocyclium bears us nlm identifiers umls id c0062674 and nci concept code c78074. smiles: oc(c1ccccc1)(cn1cc[n](cc1)(c)c)c1ccccc1. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. homatropine. this classification denotes an antimuscarinic agent with the molecular formula c17h24no3.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 68jrs2hc1c, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-((hydroxyphenylacetyl)oxy)-8,8-dimethyl-, bromide, endo- but generally known as homatropine methylbromide, which bears us nih compound identifier 6646. european medicines agency schedules homatropine methylbromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08048mig. the term homatropine methylbromide is an international non-proprietary name. most nations schedule homatropine under hs 29399990 and sitc 54149. as of q4 2014, homatropine remains the us fda preferred term for this commodity. homatropine bears us nlm identifiers umls id c0062922 and nci concept code c61783. smiles: br.o(c1cc2[n](c(cc2)c1)(c)c)c(=o)c(o)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. isopropamide. this classification denotes an anticholinergic agent with the molecular formula c23h33n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 8b9i31h724, chemically known as 4-(diisopropylamino)-2,2-diphenylbutyramide methiodide but generally known as isopropamide, which bears us nih compound identifier 3775. european medicines agency schedules isopropamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02799mig. world health organization schedules isopropamide in its anatomical therapeutic chemical (atc) classification. isopropamide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, isopropamide remains the us fda preferred term for this commodity. isopropamide bears us nlm identifiers umls id c0301373 and nci concept code c73139. smiles: o=c(n)c(cc[n](c(c)c)(c(c)c)c)(c1ccccc1)c1ccccc1. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. methylatropine. this classification denotes a parasympatholytic with the molecular formula c18h26no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 80719i460h, chemically known as 8-azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8,8-dimethyl-, endo-(+-)- but generally known as methylatropine, which bears us nih compound identifier 5861. world health organization schedules methylatropine in its anatomical therapeutic chemical (atc) classification. smiles: c[n+]1(c2ccc1cc(c2)oc(=o)c(co)c3=cc=cc=c3)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. leiopyrrole. this classification denotes an anticholinergic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s1uro6678t. european medicines agency schedules leiopyrrole in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08426mig. leiopyrrole generally arises in the molecular formula c23h28n2o. the term leiopyrrole is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5.) leiopyrrole is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule leiopyrrole under hs 29339990 and sitc 51577. as of q4 2014, leiopyrrole remains the us fda preferred term for this commodity. leiopyrrole bears us nlm identifiers umls id c0603497 and nci concept code c81460. smiles: o(ccn(cc)cc)c1c(n2c(ccc2c)c2ccccc2)cccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. mebeverine. this classification denotes an anticholinergic agent with the molecular formula c25h35no5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7f80cc3nnv, chemically known as 4-(ethyl(2-(4-methoxyphenyl)-1-methylethyl)amino)butyl 3,4-dimethoxybenzoate but generally known as mebeverine, which bears us nih compound identifier 4031. european medicines agency schedules mebeverine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08662mig. the term mebeverine is an international non-proprietary name or inn (see who inn reference publication, volume 13 no. 1, 1999, list 41). world health organization schedules mebeverine in its anatomical therapeutic chemical (atc) classification. mebeverine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule mebeverine under hs 29225000 and sitc 51467. as of q4 2014, mebeverine remains the us fda preferred term for this commodity. mebeverine bears us nlm identifiers umls id c0065832 and nci concept code c83909. smiles: o(ccccn(c(cc1ccc(oc)cc1)c)cc)c(=o)c1cc(oc)c(oc)cc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. mepenzolate. this classification denotes an antimuscarinic agent with the molecular formula c21h26no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier onw3lb39p7, chemically known as 3-hydroxy-1, 1-dimethylpiperidinium bromide benzilate but generally known as mepenzolate, which bears us nih compound identifier 4057. european medicines agency schedules mepenzolate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14513mig. world health organization schedules mepenzolate in its anatomical therapeutic chemical (atc) classification. mepenzolate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, mepenzolate remains the us fda preferred term for this commodity. mepenzolate bears us nlm identifiers umls id c0360172 and nci concept code c61830. smiles: o(c1c[n](ccc1)(c)c)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. methantheline. this classification denotes an antimuscarinic agent with the molecular formula c21h26no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 36ei79tx7i, chemically known as xanthene-9-carboxylic acid, ester with diethyl(2-hydroxyethyl)methylammonium bromide but generally known as methantheline, which bears us nih compound identifier 4097. world health organization schedules methantheline in its anatomical therapeutic chemical (atc) classification. as of q4 2014, methantheline remains the us fda preferred term for this commodity. methantheline bears us nlm identifiers umls id c0025624 and nci concept code c83951. smiles: cc[n+](c)(cc)ccoc(=o)c1c2=cc=cc=c2oc3=cc=cc=c13. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. methixene or metixene. this classification denotes an antiparkinsonian agent with the molecular formula c20h23ns, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 32vy6l26zw, chemically known as 1-pipecoline, 3-(thioxanthen-9-yl)methyl-, hydrochloride but generally known as methixene, which bears us nih compound identifier 4167. european medicines agency schedules metixene in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08897mig. the term methixene is an international non-proprietary name. world health organization schedules methixene in its anatomical therapeutic chemical (atc) classification. methixene or metixene bears us nlm identifiers umls id c0066139 and nci concept code c74162. smiles: cn1cccc(c1)cc2c3=cc=cc=c3sc4=cc=cc=c24.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. methscopolamine or methylscopolamine. this classification denotes an antimuscarinic agent with the molecular formula c18h24no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier vdr09vtq8u, chemically known as scopolammonium, n-methylbromide but generally known as methscopolamine, which bears us nih compound identifier 441342. european medicines agency schedules methscopolamine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub32123. methscopolamine or methylscopolamine bears us nlm identifiers umls id c0301374 and nci concept code c76001. smiles: br.o1c2c3[n](c(c12)cc(oc(=o)c(co)c1ccccc1)c3)(c)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. prifinium. this classification denotes an anticholinergic agent with the molecular structure c22h28n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier, 3c7ttk1k7k chemically known as 3-(diphenylmethylene)-1,1-diethyl-2-methylpyrrolidinium but generally known as prifinium, which bears us nih compound identifier 4905. european medicines agency schedules prifinium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04037mig. as of q4 2014, prifinium remains the us fda preferred term for this commodity. prifinium bears us nlm identifiers umls id c0771424 and nci concept code c84105. smiles: [n]1(c(/c(=c(/c2ccccc2)c2ccccc2)cc1)c)(cc)cc.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. obidoxime. this classification denotes an anticholinergic agent with the molecular formula c14h16n4o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier n6kne1qa9o, chemically known as 4,4-bis-(hydroxyiminomethyl)-1,1-oxydimethylen-dipyridinium-kation but generally known as obidoxime, which bears us nih compound identifier 5485192. european medicines agency schedules obidoxime in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14676mig. world health organization schedules obidoxime in its anatomical therapeutic chemical (atc) classification. obidoxime is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, obidoxime remains the us fda preferred term for this commodity. obidoxime bears us nlm identifiers umls id c0086728 and nci concept code c84023. smiles: o(cn1cc/c(=c/[nh]=o)cc1)cn1cc/c(=c/[nh]=o)cc1. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. otenzepad. this classification denotes an antimuscarinic agent with the molecular formula c24h31n5o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier om7j0xal0s, chemically known as 6h-pyrido(2,3-b)(1,4)benzodiazepin-6-one, 5,11-dihydro-11-((2-((diethylamino)methyl)-7-piperidinyl)acetyl)- but generally known as otenzepad, which bears us nih compound identifier 107867. european medicines agency schedules otenzepad in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09478mig. the term otenzepad is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). otenzepad is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule otenzepad under hs 29333999 and sitc 51574. as of q4 2014, otenzepad remains the us fda preferred term for this commodity. otenzepad bears us nlm identifiers umls id c0090085 and nci concept code c75279. smiles: o=c(n1c2c(c(=o)[nh]c3c1nccc3)cccc2)cn1c(cccc1)cn(cc)cc.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. otilonium. this classification denotes an antimuscarinic agent with the molecular formula c29h43n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 21hn3n72pv, chemically known as ethanaminium, n,n-diethyl-n-methyl-2-((4-((2-(octyloxy)benzoyl)amino)benzoyl)oxy)-, bromide but generally known as otilonium, which bears us nih compound identifier 72092. european medicines agency schedules otilonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03554mig. the term otilonium is an international non-proprietary name or inn (see who inn reference publication, volume 32, no 10 1978, list 18). world health organization schedules otilonium bromide in its anatomical therapeutic chemical (atc) classification. as of q4 2014, otilonium remains the us fda preferred term for this commodity. smiles: ccccccccoc1=cc=cc=c1c(=o)nc2=cc=c(c=c2)c(=o)occ[n+](c)(cc)cc.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. oxybutynin. this classification denotes an antimuscarinic agent with the molecular formula c22h31no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k9p6mc7092, chemically known as cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester but generally known as oxybutynin, which bears us nih compound identifier 4634. european medicines agency schedules oxybutynin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09558mig. the term oxybutynin is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules oxybutynin in its anatomical therapeutic chemical (atc) classification. oxybutynin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule oxybutynin under hs 29221980 and sitc 51461. as of q4 2014, oxybutynin remains the us fda preferred term for this commodity. oxybutynin bears us nlm identifiers umls id c0069805 and nci concept code c47647. smiles: oc(c1ccccc1)(c1ccccc1)c(=o)occ#ccn(cc)cc.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. oxyphenonium. this classification denotes an antimuscarinic agent with the molecular formula c21h34no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier d2g5508y7i, chemically known as ethanaminium, 2-((cyclohexylhydroxyphenylacetyl)oxy)-n,n-diethyl-n-methyl- but generally known as oxyphenonium, which bears us nih compound identifier 5749. european medicines agency schedules oxyphenonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14736mig. world health organization schedules oxyphenonium in its anatomical therapeutic chemical (atc) classification. oxyphenonium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, oxyphenonium remains the us fda preferred term for this commodity. oxyphenonium bears us nlm identifiers umls id c0030082 and nci concept code c78076. smiles: oc(c1ccccc1)(c1ccccc1)c(=o)occ[n](cc)(cc)c. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pipenzolate. this classification denotes a piperidine with the molecular formula c22h28no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier rs3k5yxv34, chemically known as 1-ethyl-3-hydroxy-1-methyl-piperidinium bromide, benzilic acid ester but generally known as pipenzolate, which bears us nih compound identifier 4832. european medicines agency schedules pipenzolate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03838mig. world health organization schedules pipenzolate in its anatomical therapeutic chemical (atc) classification. pipenzolate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, pipenzolate remains the us fda preferred term for this commodity. smiles: o(c1c[n](ccc1)(cc)c)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. piperidolate. this classification denotes a diphenylacetic acid and piperidine with the molecular formula c21h25no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier rjo31255v9, chemically known as 3-piperidinol, 1-ethyl-, diphenylacetate (ester) but generally known as piperidolate, which bears us nih compound identifier 4839. european medicines agency schedules piperidolate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09870mig. world health organization schedules piperidolate in its anatomical therapeutic chemical (atc) classification. piperidolate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule piperidolate under hs 29333999 and sitc 51574. as of q4 2014, piperidolate remains the us fda preferred term for this commodity. smiles: o(c1cccn(c1)cc)c(=o)c(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. solifenacin. this classification denotes an antimuscarinic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier a8910sqj1u. european medicines agency schedules solifenacin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub21589. solifenacin generally arises in the molecular formula c23h26n2o2. the term solifenacin is an international non-proprietary name or inn (see who inn reference publication, volume 16., no. 1.2002, list 47.) most nations schedule solifenacin under hs 29334990 and sitc 51575. as of q4 2014, solifenacin remains the us fda preferred term for this commodity. solifenacin bears us nlm identifiers umls id c1099677 and nci concept code c75284. smiles: o(c1c2ccn(c1)cc2)c(=o)n1c(c2c(cc1)cccc2)c1ccccc1.oc(=o)ccc(=o)o.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tiemonium. this classification denotes an antimuscarinic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5y5lz9a0kv. european medicines agency schedules tiemonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub15570mig. the term tiemonium is an international non-proprietary name or inn. as of q4 2014, tiemonium remains the us fda preferred term for this commodity. tiemonium bears us nlm identifiers umls id c0771438 and nci concept code c84209. smiles: c[n+]1(ccocc1)ccc(c2=cc=cc=c2)(c3=cc=cs3)o.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tifenamil. this classification denotes an antimuscarinic agent with the molecular formula c20h25nos, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier gx4d5197dt, chemically known as benzeneethanethioic acid, alpha-phenyl-, s-(2-(diethylamino)ethyl) ester but generally known as thiphenamil, which bears us nih compound identifier 11061. european medicines agency schedules tifenamil in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11038mig. the term tifenamil is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). most nations schedule tifenamil under hs 29309085 and sitc 51549. smiles: ccn(cc)ccsc(=o)c(c1=cc=cc=c1)c2=cc=cc=c2.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. timepidium. this classification denotes an antimuscarinic agent with the molecular formula c17h22nos2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier c1ws2xh3k4, chemically known as 3-(dithiophen-2-ylmethylidene)-5-methoxy-1,1-dimethylpiperidin-1-ium but generally known as timepidium, which bears us nih compound identifier 5476. european medicines agency schedules timepidium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04874mig. the term timepidium is an international non-proprietary name or inn (see who inn reference publication, volume 27, no. 10 1973, list 13). world health organization schedules timepidium bromide in its anatomical therapeutic chemical (atc) classification. as of q4 2014, timepidium remains the us fda preferred term for this commodity. timepidium bears us nlm identifiers umls id c1620337 and nci concept code c87647. smiles: c[n+]1(cc(cc(=c(c2=cc=cs2)c3=cc=cs3)c1)oc)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. zamifenacin. this classification denotes an antimuscarinic agent with the molecular formula c27h29no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier y88q418y7m, chemically known as piperidine, 1-(2-(1,3-benzodioxol-5-yl)ethyl)-3-(diphenylmethoxy)-, (+-)- but generally known as zamifenacin, which bears us nih compound identifier 124431. european medicines agency schedules zamifenacin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00136mig. the term zamifenacin is an international non-proprietary name or inn (see who inn reference publication, volume 7, no3, 1993, list 33). zamifenacin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule zamifenacin under hs 29349990 and sitc 51579. as of q4 2014, zamifenacin remains the us fda preferred term for this commodity. zamifenacin bears us nlm identifiers umls id c0386392 and nci concept code c66682. smiles: o(c1cn(ccc1)ccc1cc2ococ2cc1)c(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tolterodine. this classification denotes an antimuscarinic agent, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier whe7a56u7k. european medicines agency schedules tolterodine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11180mig. tolterodine generally arises in the molecular formula c22h31no. the term tolterodine is an international non-proprietary name or inn (see who inn reference publication, volume 6, no, 3 1992, list 32.) tolterodine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tolterodine under hs 29222900 and sitc 51462. as of q4 2014, tolterodine remains the us fda preferred term for this commodity. tolterodine bears us nlm identifiers umls id c0388753 and nci concept code c62083. smiles: oc1c(c(ccn(c(c)c)c(c)c)c2ccccc2)cc(cc1)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tridihexethyl. this classification denotes an antimuscarinic agent with the molecular formula c21h36no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7he50a367x, chemically known as benzenepropanaminium, gamma-cyclohexyl-n,n,n-triethyl-gamma-hydroxy-, chloride but generally known as tridihexethyl, which bears us nih compound identifier 20298. european medicines agency schedules tridihexethyl in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04951mig. world health organization schedules tridihexethyl in its anatomical therapeutic chemical (atc) classification. tridihexethyl is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, tridihexethyl remains the us fda preferred term for this commodity. tridihexethyl bears us nlm identifiers umls id c0077081 and nci concept code c78079. smiles: cl.oc(c1ccccc1)(cc[n](cc)(cc)cc)c1ccccc1. .. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. trimebutine. this classification denotes an opioid receptor agonist with the molecular formula c22h29no5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier qz1oj92e5r, chemically known as 3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutyl ester but generally known as trimebutine, which bears us nih compound identifier 5573. european medicines agency schedules trimebutine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11299mig. the term trimebutine is an international non-proprietary name or inn (see who inn reference publication, volume 24, no. 11 1970, list 10). world health organization schedules trimebutine in its anatomical therapeutic chemical (atc) classification. trimebutine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule trimebutine under hs 29221980 and sitc 51461. as of q4 2014, trimebutine remains the us fda preferred term for this commodity. trimebutine bears us nlm identifiers umls id c0041023 and nci concept code c80588. smiles: o(cc(n(c)c)(cc)c1ccccc1)c(=o)c1cc(oc)c(oc)c(oc)c1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. trospium chloride. this classification denotes an antimuscarinic agent with the molecular formula c25h30no3.cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 1e6682427e, chemically known as 6,10-ethano-5-azoniaspiro(4.5)decan-8-ol, chloride, benzilate but generally known as trospium chloride, which bears us nih compound identifier 107979. european medicines agency schedules trospium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11349mig. most nations schedule trospium chloride under hs 29399900 and sitc 54149. as of q4 2014, trospium chloride remains the us fda preferred term for this commodity. trospium chloride bears us nlm identifiers umls id c0077408 and nci concept code c61995. smiles: cl.o(c1cc2[n]3(c(cc2)c1)cccc3)c(=o)c(o)(c1ccccc1)c1ccccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tuamine or tuaminoheptane. this classification denotes an amine with the molecular formula c7h17n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier z0420gyd84, chemically known as hexylamine, 1-methyl- but generally known as tuaminoheptane, which bears us nih compound identifier 5603. european medicines agency schedules tuaminoheptane in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11360mig. world health organization schedules tuaminoheptane in its anatomical therapeutic chemical (atc) classification. tuaminoheptane is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. smiles: nc(ccccc)c.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. vamicamide. this classification denotes an antimuscarinic agent with the molecular formula c18h23n3o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ru10k34qru, chemically known as 2-pyridineacetamide, alpha-(2-(dimethylamino)propyl)-alpha-phenyl-, (r*,r*)-(+-)- but generally known as vamicamide, which bears us nih compound identifier 65967. european medicines agency schedules vamicamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00020mig. the term vamicamide is an international non-proprietary name or inn (see who inn reference publication, volume 5, no. 3 1991, list 31). vamicamide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule vamicamide under hs 29333999 and sitc 51574. as of q4 2014, vamicamide remains the us fda preferred term for this commodity. vamicamide bears us nlm identifiers umls id c0247801 and nci concept code c75289. smiles: o=c(n)c(cc(n(c)c)c)(c1ccccc1)c1ncccc1.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. tiemonium iodide. this classification denotes an antimuscarinic agent, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier fz2lz7u304. european medicines agency schedules tiemonium iodide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11031mig. tiemonium iodide generally arises in the molecular formula c18h24ino2s. the term tiemonium iodide is an international non-proprietary name or inn.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. cimetropium bromide. this classification denotes an anticholinergic agent, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 0c7m5we60q. european medicines agency schedules cimetropium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06280mig. cimetropium bromide generally arises in the molecular formula c21h28brno4. the term cimetropium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 38, no. 6, 1984, list 24.). "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. pinaverium bromide. non-atropinic antispasmodic which is used for analgesia and correction of the altered gastrointestinal transit. it acts as calcium channel blocker over the muscle fiber of the digestive tract. it dicreases the acid quantity without either modifying the gastric secretion volume or accelerating the gastric evacuation.. "
"cholinergic blocking agents. this classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.. umeclidinium. a drug administered via oral inhalation for use in adults to control wheezing, shortness of breath, coughing, and chest tightness caused by chronic obstructive pulmonary disease copd.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. . "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. chlorzoxazone. this classification denotes a muscle relaxant with the molecular formula c7h4clno2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier h0de420u8g, chemically known as 2-benzoxazolinone, 5-chloro- but generally known as chlorzoxazone, which bears us nih compound identifier 2733. european medicines agency schedules chlorzoxazone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06215mig. the term chlorzoxazone is an international non-proprietary name. world health organization schedules chlorzoxazone in its anatomical therapeutic chemical (atc) classification. chlorzoxazone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule chlorzoxazone under hs 29349990 and sitc 51579. as of q4 2014, chlorzoxazone remains the us fda preferred term for this commodity. chlorzoxazone bears us nlm identifiers umls id c0008296 and nci concept code c28926. smiles: clc1cc2[nh]c(=o)oc2cc1.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. methocarbamol. this classification denotes a muscle relaxant with the molecular formula c11h15no5, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 125od7737x, chemically known as 1,2-propanediol, 3-(o-methoxyphenoxy)-, 1-carbamate but generally known as methocarbamol, which bears us nih compound identifier 4107. european medicines agency schedules methocarbamol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08852mig. the term methocarbamol is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). world health organization schedules methocarbamol in its anatomical therapeutic chemical (atc) classification. methocarbamol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule methocarbamol under hs 29242995 and sitc 51479. as of q4 2014, methocarbamol remains the us fda preferred term for this commodity. methocarbamol bears us nlm identifiers umls id c0025659 and nci concept code c29252. smiles: coc1=cc=cc=c1occ(coc(=o)n)o.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. carisoprodol. this classification denotes a muscle relaxant with the molecular formula c12h24n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 21925k482h, chemically known as 1,3-propanediol, 2-methyl-2-propyl-, carbamate isopropylcarbamate (ester) but generally known as carisoprodol, which bears us nih compound identifier 2576. european medicines agency schedules carisoprodol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06631mig. the term carisoprodol is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). world health organization schedules carisoprodol in its anatomical therapeutic chemical (atc) classification. carisoprodol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule carisoprodol under hs 29241900 and sitc 51471. as of q4 2014, carisoprodol remains the us fda preferred term for this commodity. carisoprodol bears us nlm identifiers umls id c0702216 and nci concept code c28904. smiles: o(cc(ccc)(coc(=o)n)c)c(=o)nc(c)c.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. thiocolchicoside. this classification denotes a colchicine analog and hysterosalpingography adjunct with the molecular formula c27h33no10s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier t1x8s697gt, chemically known as colchicoside, 10-thio- (8ci) but generally known as thiocolchicoside, which bears us nih compound identifier 72067. european medicines agency schedules thiocolchicoside in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10976mig. world health organization schedules thiocolchicoside in its anatomical therapeutic chemical (atc) classification. thiocolchicoside is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule thiocolchicoside under hs 29399900 and sitc 54149. as of q4 2014, thiocolchicoside remains the us fda preferred term for this commodity. smiles: s(c1c(=o)cc2c(nc(=o)c)ccc3c(c2cc1)c(oc)c(oc)c(oc1oc(c(o)c(o)c1o)co)c3)c.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. phenprobamate. this classification denotes a carbamate with the molecular formula c10h13no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier ujz473tps0, chemically known as 1-propanol, 3-phenyl-, carbamate but generally known as phenprobamate, which bears us nih compound identifier 4770. european medicines agency schedules phenprobamate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09780mig. world health organization schedules phenprobamate in its anatomical therapeutic chemical (atc) classification. phenprobamate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule phenprobamate under hs 29242995 and sitc 51479. as of q4 2014, phenprobamate remains the us fda preferred term for this commodity. phenprobamate bears us nlm identifiers umls id c0070591 and nci concept code c98239. smiles: c1=cc=c(c=c1)cccoc(=o)n.. "
"centrally acting skeletal muscle relaxants. this classification denotes a heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. they have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. they have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in multiple sclerosis.. styramate. this classification denotes a centrally acting muscle relaxant with the molecular formula c9h11no3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier cbk7y28sp3, chemically known as 2-hydroxy-2-phenylethyl carbamate, which bears us nih compound identifier 7186. the term styramate is an international non-proprietary name or inn. european medicines agency schedules styramate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10660mig. most nations schedule styramate under hs 29242995 and sitc 51479. as of q4 2014, styramate remains the us fda preferred term for this commodity. smiles: c1=cc=c(c=c1)c(coc(=o)n)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. . "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. atracurium. this classification denotes a neuromuscular blocking agent with the molecular formula c65h82n2o18s2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 40ax66p76p, chemically known as benzenesulfonate;5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propanoate but generally known as atracurium besylate, which bears us nih compound identifier 47320. european medicines agency schedules atracurium besylate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub29313. the term atracurium besylate is an international non-proprietary name or inn. atracurium besylate is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, atracurium remains the us fda preferred term for this commodity. atracurium bears us nlm identifiers umls id c0004234 and nci concept code c76068. smiles: c[n+]1(ccc2=cc(=c(c=c2c1cc3=cc(=c(c=c3)oc)oc)oc)oc)ccc(=o)occcccoc(=o)cc[n+]4(ccc5=cc(=c(c=c5c4cc6=cc(=c(c=c6)oc)oc)oc)oc)c.c1=cc=c(c=c1)s(=o)(=o)[o-].c1=cc=c(c=c1)s(=o)(=o)[o-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. rocuronium. this classification denotes a nicotinic antagonist with the molecular formula c32h53n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier wre554rfez. european medicines agency schedules rocuronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04260mig. rocuronium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, rocuronium remains the us fda preferred term for this commodity. rocuronium bears us nlm identifiers umls id c0209337 and nci concept code c80999. smiles: o(c1c2(c(c3c(c4(c(cc3)cc(o)c(n3ccocc3)c4)c)cc2)cc1[n]1(cccc1)cc=c)c)c(=o)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. vecuronium. this classification denotes a nicotinic antagonist with the molecular formula c34h57n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 5438723848, chemically known as 5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate but generally known as vecuronium, which bears us nih compound identifier 39764. european medicines agency schedules vecuronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05084mig. world health organization schedules vecuronium in its anatomical therapeutic chemical (atc) classification. vecuronium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, vecuronium remains the us fda preferred term for this commodity. vecuronium bears us nlm identifiers umls id c0242531 and nci concept code c87317. smiles: br.o(c1c2(c(c3c(c4(c(cc3)cc(oc(=o)c)c(n3ccccc3)c4)c)cc2)cc1[n]1(ccccc1)c)c)c(=o)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. botulinum toxin. this classification denotes a peripherally-acting muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e211kpy694.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. cisatracurium. this classification denotes a nicotinic antagonist with the molecular formula c53h72n2o12, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier qx62kli41n, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but generally known as cisatracurium, which bears us nih compound identifier 62886. european medicines agency schedules cisatracurium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01319mig. world health organization schedules cisatracurium in its anatomical therapeutic chemical (atc) classification. cisatracurium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, cisatracurium remains the us fda preferred term for this commodity. cisatracurium bears us nlm identifiers umls id c1096766 and nci concept code c77365. smiles: s(=o)(=o)(o)c1ccccc1.s(=o)(=o)(o)c1ccccc1.o(c1cc2c([n](ccc2cc1oc)(ccc(=o)occcccoc(=o)cc[n]1(c(c2c(cc1)cc(oc)c(oc)c2)cc1cc(oc)c(oc)cc1)c)c)cc1cc(oc)c(oc)cc1)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. doxacurium. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m78tvm3g5z. european medicines agency schedules doxacurium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06380mig. doxacurium chloride generally arises in the molecular formula c56h78cl2n2o16. the term doxacurium chloride is an international non-proprietary name or inn (see who inn reference publication, volume 2, no. 3, 1988, list 28.) as of q4 2014, doxacurium remains the us fda preferred term for this commodity. doxacurium bears us nlm identifiers umls id c0058716 and nci concept code c81000. smiles: c[n+]1(ccc2=cc(=c(c(=c2c1cc3=cc(=c(c(=c3)oc)oc)oc)oc)oc)oc)cccoc(=o)ccc(=o)occc[n+]4(ccc5=cc(=c(c(=c5c4cc6=cc(=c(c(=c6)oc)oc)oc)oc)oc)oc)c.[cl-].[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dimethyltubocurarine or metocurine. this classification denotes a muscle relaxant with the molecular formula c40h48n2o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier v0m92g2u26. as of q4 2014, metocurine remains the us fda preferred term for this commodity. metocurine bears us nlm identifiers umls id c0066465 and nci concept code c76069. smiles: c[n+]1(ccc2=cc(=c3c=c2c1cc4=cc=c(c=c4)oc5=c6c(cc7=cc(=c(c=c7)oc)o3)[n+](ccc6=cc(=c5oc)oc)(c)c)oc)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. pancuronium. this classification denotes a muscle relaxant with the molecular formula c35h60n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j76uf062fs, chemically known as 5.alpha.-androstan-3.alpha.,17.beta.-diol, 2.beta., 16.beta.-dipipecolinio-, dibromide, diacetate but generally known as pancuronium, which bears us nih compound identifier 4675. european medicines agency schedules pancuronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03618mig. world health organization schedules pancuronium in its anatomical therapeutic chemical (atc) classification. pancuronium is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, pancuronium remains the us fda preferred term for this commodity. pancuronium bears us nlm identifiers umls id c0030310 and nci concept code c61876. smiles: o(c1c2(c(c3c(c4(c(cc3)cc(oc(=o)c)c([n]3(ccccc3)c)c4)c)cc2)cc1[n]1(ccccc1)c)c)c(=o)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. rapacuronium. this classification denotes a muscle relaxant with the molecular formula c37h61n2o4.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 65q4qdg4kc, chemically known as piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxopropoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide but generally known as rapacuronium bromide, which bears us nih compound identifier 177969. european medicines agency schedules rapacuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10260mig. the term rapacuronium bromide is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 2 1999, list 40). as of q4 2014, rapacuronium remains the us fda preferred term for this commodity. smiles: ccc(=o)oc1c(cc2c1(ccc3c2ccc4c3(cc(c(c4)oc(=o)c)n5ccccc5)c)c)[n+]6(ccccc6)cc=c.[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. tubocurarine. this classification denotes a nicotinic antagonist and neuromuscular nondepolarizing agent with the molecular formula c37h41n2o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier w9yxs298bm, chemically known as 13h-4,6:21,24-dietheno-8,12-metheno-1h-pyrido(3,2:14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13ar,25as)- but generally known as tubocurarine, which bears us nih compound identifier 6000. european medicines agency schedules tubocurarine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub15635mig. world health organization schedules tubocurarine in its anatomical therapeutic chemical (atc) classification. tubocurarine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. as of q4 2014, tubocurarine remains the us fda preferred term for this commodity. smiles: cn1ccc2=cc(=c3c=c2c1cc4=cc=c(c=c4)oc5=c6c(cc7=cc(=c(c=c7)o)o3)[n+](ccc6=cc(=c5o)oc)(c)c)oc.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. pipecuronium. this classification denotes a muscle relaxant with the molecular formula c35h62n4o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier r6zty81re1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but generally known as pipecurium bromide, which bears us nih compound identifier 65332. european medicines agency schedules pipecuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14880mig. the term pipecuronium bromide is an international non-proprietary name or inn (see who inn reference publication, volume 33, no. 10 1979, list 19). world health organization schedules pipecurium bromide in its anatomical therapeutic chemical (atc) classification. as of q4 2014, pipecuronium remains the us fda preferred term for this commodity. pipecuronium bears us nlm identifiers umls id c0071102 and nci concept code c77368. smiles: cc(=o)oc1cc2ccc3c(c2(cc1n4cc[n+](cc4)(c)c)c)ccc5(c3cc(c5oc(=o)c)n6cc[n+](cc6)(c)c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. cinflumide. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier f0xvl451mo. european medicines agency schedules cinflumide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06296mig. cinflumide generally arises in the molecular formula c12h12fno. the term cinflumide is an international non-proprietary name or inn (see who inn reference publication, volume 39, no. 5, 1985, list 25.) cinflumide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule cinflumide under hs 29242995 and sitc 51479. as of q4 2014, cinflumide remains the us fda preferred term for this commodity. cinflumide bears us nlm identifiers umls id c1880086 and nci concept code c65330. smiles: c1cc1nc(=o)/c=c/c2=cc(=cc=c2)f.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. abobotulinumtoxina. this classification denotes a peripherally-acting muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e211kpy694.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. afloqualone. this classification denotes a muscle relaxant with the molecular formula c16h14fn3o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier co4u2c8orz, chemically known as 6-amino-3,4-dihydro-2-fluoromethyl-3-(2-methylphenyl)-4-chinazolinon but generally known as afloqualone, which bears us nih compound identifier 2040. european medicines agency schedules afloqualone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05281mig. the term afloqualone is an international non-proprietary name or inn (see who inn reference publication, volume 34, no. 10 1980, list 20). afloqualone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule afloqualone under hs 29335995 and sitc 51576. as of q4 2014, afloqualone remains the us fda preferred term for this commodity. afloqualone bears us nlm identifiers umls id c0050939 and nci concept code c83522. smiles: fcc1n(c2c(cccc2)c)c(=o)c2c(n1)ccc(n)c2.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. alcuronium. this classification denotes a nicotinic antagonist with the molecular formula c44h50n4o2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier s8u3j5w06n. european medicines agency schedules alcuronium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub12766mig. the term alcuronium is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7.) as of q4 2014, alcuronium remains the us fda preferred term for this commodity. smiles: oc/c=c1/c2cc3[n](ccc43c3n(c=c5c6n(c=c23)c2c(c36c6[n](cc3)(cc(=c\\co)\\c5c6)cc=c)cccc2)c2c4cccc2)(c1)cc=c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. baclofen. this classification denotes a muscle relaxant with the molecular formula c10h12clno2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier h789n3fke8, chemically known as hydrocinnamic acid, beta-(aminomethyl)-p-chloro- but generally known as baclofen, which bears us nih compound identifier 2284. european medicines agency schedules baclofen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05667mig. the term baclofen is an international non-proprietary name or inn (see who inn reference publication, volume 25 , no. 10 1971, list 11). world health organization schedules baclofen in its anatomical therapeutic chemical (atc) classification. baclofen is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule baclofen under hs 29224995 and sitc 51465. as of q4 2014, baclofen remains the us fda preferred term for this commodity. baclofen bears us nlm identifiers umls id c0004609 and nci concept code c28858. smiles: c1=cc(=cc=c1c(cc(=o)o)cn)cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. butamisole. this classification denotes an antihelminthic agent with the molecular formula c15h19n3os, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier xvb7982801, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thiazol-6-yl)phenyl)-, (-)- but generally known as butamisole, which bears us nih compound identifier 166572. butamisole most often comes in base and hydrochloride forms. european medicines agency schedules butamisole in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06001mig. the term butamisole is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16). butamisole is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule butamisole under hs 29349990 and sitc 51579. as of q4 2014, butamisole remains the us fda preferred term for this commodity. butamisole bears us nlm identifiers umls id c0054237 and nci concept code c79921. smiles: s1c2=nc(cn2cc1)c1cc(nc(=o)c(c)c)ccc1.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. butamisole hydrochloride. this classification denotes an antihelminthic agent with the molecular formula c15h19n3os.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier qgm18599h5, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thizol-6-yl)phenyl)-, monohydrochloride, (-)- but generally known as butamisole hydrochloride, which bears us nih compound identifier 166571. most nations schedule butamisole hydrochloride under hs 29349990 and sitc 51579. as of q4 2014, butamisole hydrochloride remains the us fda preferred term for this commodity. butamisole hydrochloride bears us nlm identifiers umls id c0700565 and nci concept code c79919. smiles: cc(c)c(=o)nc1=cc=cc(=c1)c2cn3ccsc3=n2.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. tubocurarine or d-tubocurarine or dtc. this classification denotes a muscle relaxant with the molecular formula c40h48n2o6, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier v0m92g2u26. smiles: c[n+]1(ccc2=cc(=c3c=c2c1cc4=cc=c(c=c4)oc5=c6c(cc7=cc(=c(c=c7)oc)o3)[n+](ccc6=cc(=c5oc)oc)(c)c)oc)c. smiles: c[n+]1(ccc2=cc(=c3c=c2c1cc4=cc=c(c=c4)oc5=c6c(cc7=cc(=c(c=c7)oc)o3)[n+](ccc6=cc(=c5oc)oc)(c)c)oc)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. clodanolene. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 96l9g9bl3x. european medicines agency schedules clodanolene in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06689mig. clodanolene generally arises in the molecular formula c14h9cl2n3o3. the term clodanolene is an international non-proprietary name or inn (see who inn reference publication, volume 30, no. 10 1976, list 16.) clodanolene is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule clodanolene under hs 29349990 and sitc 51579. as of q4 2014, clodanolene remains the us fda preferred term for this commodity. clodanolene bears us nlm identifiers umls id c0055902 and nci concept code c80981. smiles: clc1cc(c2oc(cc2)/c=n/n2cc(=o)nc2=o)ccc1cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. cyclobenzaprine. this classification denotes a muscle relaxant with the molecular formula c20h21n, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 69o5wqq5ti, chemically known as 10,11-dehydroamitriptyline but generally known as cyclobenzaprine, which bears us nih compound identifier 2895. european medicines agency schedules cyclobenzaprine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06849mig. the term cyclobenzaprine is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). world health organization schedules cyclobenzaprine in its anatomical therapeutic chemical (atc) classification. cyclobenzaprine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule cyclobenzaprine under hs 29214980 and sitc 51454. as of q4 2014, cyclobenzaprine remains the us fda preferred term for this commodity. cyclobenzaprine bears us nlm identifiers umls id c0056732 and nci concept code c28947. smiles: n(cc/c=c1\\c2c(c=cc3c1cccc3)cccc2)(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dantrolene. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier f64qu97qcr. european medicines agency schedules dantrolene in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06903mig. dantrolene generally arises in the molecular formula c14h10n4o5. the term dantrolene is an international non-proprietary name or inn (see who inn reference publication, volume 21 no. 12 1967, list 7.) dantrolene is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule dantrolene under hs 29349990 and sitc 51579. as of q4 2014, dantrolene remains the us fda preferred term for this commodity. dantrolene bears us nlm identifiers umls id c0010976 and nci concept code c61697. smiles: o1c(c2ccc([n](=o)o)cc2)ccc1/c=n/n1cc(=o)nc1=o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dantrolene sodium. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 287m0347ev. european medicines agency schedules dantrolene sodium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01553mig. dantrolene sodium generally arises in the molecular formula c14h9n4nao5. the term dantrolene sodium is a united states adopted name designation. most nations schedule dantrolene sodium under hs 29349990 and sitc 51579. as of q4 2014, dantrolene sodium remains the us fda preferred term for this commodity. dantrolene sodium bears us nlm identifiers umls id c0010977 and nci concept code c61698. smiles: c1c(=o)n=c(n1n=cc2=cc=c(o2)c3=cc=c(c=c3)[n+](=o)[o-])[o-].[na+].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. decamethonium. this classification denotes a muscle relaxant with the molecular formula c16h38n2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier c1cg1s3t2w, chemically known as 1,10-decanediaminium, n,n,n,n,n,n-hexamethyl but generally known as decamethonium bromide, which bears us nih compound identifier 2968. european medicines agency schedules decamethonium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub01568mig. the term decamethonium is an international non-proprietary name. as of q4 2014, decamethonium remains the us fda preferred term for this commodity. decamethonium bears us nlm identifiers umls id c0057231 and nci concept code c77363. smiles: c[n+](c)(c)cccccccccc[n+](c)(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. denpidazone. this classification denotes a muscle relaxant with the molecular formula c20h20n2o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier e7n3fx2t1j, chemically known as 3,6-pyridazinedione, 1,2-dihydro-4-butyl-5-hydroxy-1,2-diphenyl- but generally known as denpidazone, which bears us nih compound identifier 206004. european medicines agency schedules denpidazone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06979mig. the term denpidazone is an international non-proprietary name or inn (see who inn reference publication, volume 25 , no. 10 1971, list 11). denpidazone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule denpidazone under hs 29339990 and sitc 51577. as of q4 2014, denpidazone remains the us fda preferred term for this commodity. denpidazone bears us nlm identifiers umls id c2699589 and nci concept code c77599. smiles: oc1n(n(c(=o)c(=o)c1cccc)c1ccccc1)c1ccccc1.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. idrocilamide. this classification denotes a muscle relaxant with the molecular formula c11h13no2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 6c816lub1o, chemically known as 2-propenamide, n-(2-hydroxyethyl)-3-phenyl- but generally known as idrocilamide, which bears us nih compound identifier 1550874. european medicines agency schedules idrocilamide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08121mig. the term idrocilamide is an international non-proprietary name. world health organization schedules idrocilamide in its anatomical therapeutic chemical (atc) classification. idrocilamide is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule idrocilamide under hs 29242995 and sitc 51479. as of q4 2014, idrocilamide remains the us fda preferred term for this commodity. idrocilamide bears us nlm identifiers umls id c0054086 and nci concept code c74280. smiles: c1=cc=c(c=c1)/c=c/c(=o)ncco.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dotefonium. this classification denotes a muscle relaxant with the molecular formula c20h27n2o2s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier f41a22a3kv, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)- but generally known as dotefonium, which bears us nih compound identifier 71913. european medicines agency schedules dotefonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06379mig. the term dotefonium is an international non-proprietary name or inn (see who inn reference publication, volume 25 , no. 10 1971, list 11). as of q4 2014, dotefonium remains the us fda preferred term for this commodity. dotefonium bears us nlm identifiers umls id c2828324 and nci concept code c87490. smiles: cn(cc[n+]1(cccc1)c)c(=o)c(c2=cc=cc=c2)(c3=cc=cs3)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. fazadinium bromide. this classification denotes a nicotinic antagonist with the molecular formula c28h24n6.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 8wv5538lfk, chemically known as 1,1-azobis(3-methyl-2-phenylimidazo(1,2-a)pyridinium) dibromide but generally known as fazadinium bromide, which bears us nih compound identifier 5489112. european medicines agency schedules fazadinium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07516mig. the term fazadinium bromide is an international non-proprietary name or inn (see who inn reference publication, volume 29, no. 10 1975, list 15). world health organization schedules fazadinium bromide in its anatomical therapeutic chemical (atc) classification. most nations schedule fazadinium bromide under hs 29339990 and sitc 51577. as of q4 2014, fazadinium bromide remains the us fda preferred term for this commodity. fazadinium bromide bears us nlm identifiers umls id c0015707 and nci concept code c80530. smiles: br.br.n1(/n=n/n2c(c3ccccc3)c([n]3c2cccc3)c)c(c2ccccc2)c([n]2c1cccc2)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. fenyramidol or phenyramidol. this classification denotes a muscle relaxant with the molecular formula c13h14n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier r3v02wl7o3, chemically known as benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride but generally known as fenyramidol, which bears us nih compound identifier 9470. european medicines agency schedules fenyramidol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07602mig. the term fenyramidol is an international non-proprietary name or inn (see who inn reference publication, volume 19 1975, list 5). world health organization schedules fenyramidol in its anatomical therapeutic chemical (atc) classification. fenyramidol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. fenyramidol or phenyramidol bears us nlm identifiers umls id c1510448 and nci concept code c84054. smiles: c1=cc=c(c=c1)c(cnc2=cc=cc=n2)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. fenyripol. this classification denotes a muscle relaxant with the molecular formula c12h13n3o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier il6zsg07i5, chemically known as benzyl alcohol, .alpha.-(2-pyridyl-aminomethyl)-, hydrochloride but generally known as fenyripol, which bears us nih compound identifier 9470. european medicines agency schedules fenyripol in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07603mig. the term fenyripol is an international non-proprietary name. fenyripol is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule fenyripol under hs 29335995 and sitc 51576. as of q4 2014, fenyripol remains the us fda preferred term for this commodity. fenyripol bears us nlm identifiers umls id c2825400 and nci concept code c80983. smiles: c1=cc=c(c=c1)c(cnc2=cc=cc=n2)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. hexcarbacholine. this classification denotes a muscle relaxant with the molecular formula c18h40n4o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier nm87thp11p, chemically known as n,n,n,n,n,n-hexamethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecamethylendiammonium dibromid but generally known as hexcarbacholine bromide, which bears us nih compound identifier 71495. european medicines agency schedules hexcarbacholine bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08034mig. the term hexcarbacholine bromide is an international non-proprietary name. as of q4 2014, hexcarbacholine remains the us fda preferred term for this commodity. hexcarbacholine bears us nlm identifiers umls id c2828259 and nci concept code c87312. smiles: br.br.o(cc[n](c)(c)c)c(=o)nccccccnc(=o)occ[n](c)(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. inaperisone. this classification denotes a muscle relaxant with the molecular formula c16h23no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0qac3p785o, chemically known as 1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-, but generally known as inaperisone, which bears us nih compound identifier 65860. european medicines agency schedules inaperisone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08162mig. the term inaperisone is an international non-proprietary name or inn (see who inn reference publication, volume 3, no. 3, 1989, list 29). inaperisone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule inaperisone under hs 29339990 and sitc 51577. as of q4 2014, inaperisone remains the us fda preferred term for this commodity. inaperisone bears us nlm identifiers umls id c0062996 and nci concept code c65905. smiles: o=c(c(cn1cccc1)c)c1ccc(cc1)cc.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. lanperisone. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier to2jp2g53h. european medicines agency schedules lanperisone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08400mig. lanperisone generally arises in the molecular formula c15h18f3no. the term lanperisone is an international non-proprietary name or inn (see who inn reference publication, volume 9, no. 3, 1995, list 35.) lanperisone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule lanperisone under hs 29339990 and sitc 51577. as of q4 2014, lanperisone remains the us fda preferred term for this commodity. lanperisone bears us nlm identifiers umls id c2697881 and nci concept code c79785. smiles: fc(f)(f)c1ccc(c(=o)c(cn2cccc2)c)cc1.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mephenesin. this classification denotes a muscle relaxant with the molecular formula c10h14o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7b8pir2954, chemically known as 1,2-propanediol, 3-(o-tolyloxy)- but generally known as mephenesin, which bears us nih compound identifier 4059. european medicines agency schedules mephenesin in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08746mig. the term mephenesin is an international non-proprietary name. world health organization schedules mephenesin in its anatomical therapeutic chemical (atc) classification. mephenesin is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule mephenesin under hs 29094990 and sitc 51617. as of q4 2014, mephenesin remains the us fda preferred term for this commodity. mephenesin bears us nlm identifiers umls id c0025379 and nci concept code c76773. smiles: cc1=cc=cc=c1occ(co)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mephenesin nicotinate. this classification denotes a muscle relaxant with the molecular formula c16h17no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 9490c46o95. most nations schedule mephenesin nicotinate under hs 29094990 and sitc 51617. as of q4 2014, mephenesin nicotinate remains the us fda preferred term for this commodity. smiles: cc1=cc=cc=c1occ(coc(=o)n)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mephenoxalone. this classification denotes a muscle relaxant with the molecular formula c11h13no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier cz87t54w8w, chemically known as 2-oxazolidinone, 5-((o-methoxyphenoxy)methyl)- but generally known as mephenoxalone, which bears us nih compound identifier 6257. european medicines agency schedules mephenoxalone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08747mig. the term mephenoxalone is an international non-proprietary name or inn (see who inn reference publication, volume 16, no. 3 1962, list 4). world health organization schedules mephenoxalone in its anatomical therapeutic chemical (atc) classification. mephenoxalone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule mephenoxalone under hs 29349990 and sitc 51579. as of q4 2014, mephenoxalone remains the us fda preferred term for this commodity. mephenoxalone bears us nlm identifiers umls id c0065959 and nci concept code c83930. smiles: coc1=cc=cc=c1occ2cnc(=o)o2.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mivacurium chyloride. this classification denotes a muscle relaxant with the molecular formula c58h80n2o14.2cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 600zg213c3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but generally known as mivacurium chloride, which bears us nih compound identifier 5281080. european medicines agency schedules mivacurium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09014mig. the term mivacurium chloride is an international non-proprietary name or inn (see who inn reference publication, volume 2, no. 3, 1988, list 28). world health organization schedules mivacurium chloride in its anatomical therapeutic chemical (atc) classification. smiles: c[n+]1(ccc2=cc(=c(c=c2c1cc3=cc(=c(c(=c3)oc)oc)oc)oc)oc)cccoc(=o)ccc=cccc(=o)occc[n+]4(ccc5=cc(=c(c=c5c4cc6=cc(=c(c(=c6)oc)oc)oc)oc)oc)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. nelezaprine. this classification denotes a muscle relaxant with the molecular formula c18h21cln2, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier oc19j8o751, chemically known as (3e)-3-(9-chloro-5,6-dihydropyrrolo[1,2-c][3]benzazepin-11-ylidene)-n,n-dimethylpropan-1-amine but generally known as nelezaprine, which bears us nih compound identifier 6436130. european medicines agency schedules nelezaprine its extended eudravigilance medicinal product dictionary or xevmpd under index sub09185mig. most nations schedule nelezaprine under hs 29339930 and sitc 51577. as of q4 2014, nelezaprine remains the us fda preferred term for this commodity. nelezaprine bears us nlm identifiers umls id c2983927 and nci concept code c90893. smiles: cn(c)ccc=c1c2=cc=cn2ccc3=c1c=c(c=c3)cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. stercuronium. this classification denotes a muscle relaxant with the molecular formula c26h43n2.i, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k1477r7ddr, chemically known as (cona-4,6-dienin-3beta-yl)dimethylethylammonium iodide but generally known as stercuronium iodide, which bears us nih compound identifier 71924. european medicines agency schedules stercuronium iodide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10646mig. the term stercuronium iodide is an international non-proprietary name. as of q4 2014, stercuronium remains the us fda preferred term for this commodity. smiles: i.n1(cc23c(c4c(cc3)c3(c(=cc([n](cc)(c)c)cc3)c=c4)c)ccc2c1c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. orphenadrine. this classification denotes a muscle relaxant and antimuscarinic agent with the molecular formula c18h23no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier al805o9og9, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but generally known as orphenadrine, which bears us nih compound identifier 4601. european medicines agency schedules orphenadrine in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09471mig. orphenadrine is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule orphenadrine under hs 29221980 and sitc 51461. as of q4 2014, orphenadrine remains the us fda preferred term for this commodity. orphenadrine bears us nlm identifiers umls id c0029309 and nci concept code c61868. smiles: o(c(c1c(cccc1)c)c1ccccc1)ccn(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. oxydipentonium. this classification denotes a muscle relaxant with the molecular formula c16h38n2o, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 52j3c7381o, chemically known as trimethyl-[5-[5-(trimethylazaniumyl)pentoxy]pentyl]azanium but generally known as oxydipentonium, which bears us nih compound identifier 23560. european medicines agency schedules oxydipentonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09563mig. the term oxydipentonium is an international non-proprietary name. as of q4 2014, oxydipentonium remains the us fda preferred term for this commodity. oxydipentonium bears us nlm identifiers umls id c2828260 and nci concept code c87313. smiles: c[n+](c)(c)cccccoccccc[n+](c)(c)c.[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. promoxolane. this classification denotes a muscle relaxant with the molecular formula c10h20o3, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier jhi9rry52e, chemically known as 2,2-diisopropyl-4-methanol-1,3-dioxolane but generally known as promoxolane, which bears us nih compound identifier 10105. european medicines agency schedules promoxolane in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10091mig. the term promoxolane is an international non-proprietary name or inn (see who inn reference publication, volume 13, no. 12, 1959, list 3). promoxolane is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule promoxolane under hs 29329970 and sitc 51569. as of q4 2014, promoxolane remains the us fda preferred term for this commodity. promoxolane bears us nlm identifiers umls id c0520813 and nci concept code c82296. smiles: cc(c)c1(occ(o1)co)c(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. silperisone. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier r16sk8726x. european medicines agency schedules silperisone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10521mig. silperisone generally arises in the molecular formula c15h24fnsi. the term silperisone is an international non-proprietary name or inn (see who inn reference publication, volume 12 no. 2 1999, list 40.) silperisone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule silperisone under hs 29333999 and sitc 51574. as of q4 2014, silperisone remains the us fda preferred term for this commodity. silperisone bears us nlm identifiers umls id c1101150 and nci concept code c74281. smiles: [si](cn1ccccc1)(cc1ccc(f)cc1)(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. succinylcholine or suxamethonium or suxamethonium chloride. this classification denotes a muscle relaxant with the molecular formula c14h30n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier j2r869a8yf, chemically known as succinic acid, diester with choline iodide but generally known as succinylcholine, which bears us nih compound identifier 5314. smiles: c[n+](c)(c)ccoc(=o)ccc(=o)occ[n+](c)(c)c. smiles: c[n+](c)(c)ccoc(=o)ccc(=o)occ[n+](c)(c)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. suxethonium. this classification denotes a muscle relaxant with the molecular formula c16h34n2o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier med638szqb, chemically known as succinic acid, diester with choline iodide but generally known as suxethonium, which bears us nih compound identifier 71732. european medicines agency schedules suxethonium in its extended eudravigilance medicinal product dictionary or xevmpd under index sub15440mig. the term suxethonium is an international non-proprietary name. as of q4 2014, suxethonium remains the us fda preferred term for this commodity. suxethonium bears us nlm identifiers umls id c0605824 and nci concept code c87315. smiles: cc[n+](c)(c)ccoc(=o)ccc(=o)occ[n+](c)(c)cc.[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. tolperisone. this classification denotes a muscle relaxant with the molecular formula c16h23no, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier f5eom0ld8e, chemically known as 2,4-dimethyl-3-piperidinopropiophenone but generally known as tolperisone, which bears us nih compound identifier 5511. european medicines agency schedules tolperisone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub11173mig. the term tolperisone is an international non-proprietary name or inn (see who inn reference publication, volume 27, no. 10 1973, list 13). world health organization schedules tolperisone in its anatomical therapeutic chemical (atc) classification. tolperisone is scheduled in the u.s. international trade commissions harmonized tariff system (hts) pharmaceutical appendix. most nations schedule tolperisone under hs 29333999 and sitc 51574. as of q4 2014, tolperisone remains the us fda preferred term for this commodity. tolperisone bears us nlm identifiers umls id c0040382 and nci concept code c84219. smiles: o=c(c(cn1ccccc1)c)c1ccc(cc1)c.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. alcuronium chloride. this classification denotes a nicotinic antagonist, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 490dw6501y. european medicines agency schedules alcuronium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub05302mig. alcuronium chloride generally arises in the molecular formula c44h50n4o2.2cl. the term alcuronium chloride is an international non-proprietary name or inn (see world health organization inn reference publication, volume 21 no. 12 1967, list 7.) most nations, for tariff and trade purposes, schedule alcuronium chloride under hs 29399900 and sitc 54149. as of q4 2014, alcuronium chloride remains us fdas preferred term for this commodity. alcuronium chloride bears us nlm identifiers umls id c0205658 and nci concept code c79728. smiles: c=cc[n@@+]12[c@@h]3[c@@]4([c@h]/5n(c6c4cccc6)/c=c/7\\[c@@h]8n(c9c(cccc9)[c@]84[c@h]6[n@+](c/c(=c/co)/[c@@h]7c6)(cc4)cc=c)/c=c5/[c@@h](c3)/c(=c\\co)/c1)cc2.[cl-].[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. baclofen hydrochloride. this classification denotes a muscle relaxant with the molecular formula c10h12clno2.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 64ose3996v. most nations, for tariff and trade purposes, schedule baclofen hydrochloride under hs 29224995. as of q4 2014, baclofen hydrochloride remains us fdas preferred term for this commodity. baclofen hydrochloride bears us nlm identifiers umls id c2983921 and nci concept code c90887. smiles: c1cc(ccc1c(cc(=o)o)cn)cl.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. cisatracurium besilate. this classification denotes a nicotinic antagonist with the molecular formula c53h72n2o12.2c6h5o3s, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 80ys8o1mbs, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but more generally known as cisatracurium besilate, which bears us nih compound identifier 62886. european medicines agency schedules cisatracurium besilate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub07480mig. the term cisatracurium besilate is an international non-proprietary name or inn (see world health organization inn reference publication, volume 10, no. 3, 1996, list 36). most nations, for tariff and trade purposes, schedule cisatracurium besilate under hs 29334990 and sitc 51575. smiles: c[n@@+]1(ccc2cc(c(cc2[c@h]1cc3ccc(c(c3)oc)oc)oc)oc)ccc(=o)occcccoc(=o)cc[n@+]4(ccc5cc(c(cc5[c@h]4cc6ccc(c(c6)oc)oc)oc)oc)c.c1ccc(cc1)s(=o)(=o)[o-].c1ccc(cc1)s(=o)(=o)[o-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. cyclobenzaprine hydrochloride. this classification denotes a muscle relaxant and antidepressant agent with the molecular formula c20h21n.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 0ve05jys2p, chemically known as 10,11-dehydroamitriptyline but more generally known as cyclobenzaprine hydrochloride, which bears us nih compound identifier 2895. european medicines agency schedules cyclobenzaprine hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub13514mig. most nations, for tariff and trade purposes, schedule cyclobenzaprine hydrochloride under hs 29214980 and sitc 51454. as of q4 2014, cyclobenzaprine hydrochloride remains us fdas preferred term for this commodity. cyclobenzaprine hydrochloride bears us nlm identifiers umls id c0125988 and nci concept code c47465. smiles: cn(c)ccc=c1c2ccccc2c=cc3c1cccc3.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dantrolene sodium anhydrous. this classification denotes a muscle relaxant with the molecular formula c14h9n4o5.na, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 28f0g1e0vf, chemically known as 1-((5-(p-nitrophenyl)furfurylidene)amino)hydantoin sodium salt, but more generally known as dantrolene sodium anhydrous, which bears us nih compound identifier 6604100. european medicines agency schedules dantrolene sodium anhydrous or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06903mig. most nations, for tariff purposes, schedule dantrolene sodium anhydrous under hs 29349990. smiles: c1cc(ccc1c2ccc(o2)/c=n/n3cc(=o)[n-]c3=o)[n+](=o)[o-].[na+].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. decamethonium bromide. this classification denotes a muscle relaxant with the molecular formula c16h38n2.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 55c6rk944k, chemically known as 1,10-decanediaminium, n,n,n,n,n,n-hexamethyl-, monobromide but more generally known as decamethonium bromide, which bears us nih compound identifier 2968. european medicines agency schedules decamethonium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06930mig. the term decamethonium bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule decamethonium bromide under hs 29239000 and sitc 51481. as of q4 2014, decamethonium bromide remains us fdas preferred term for this commodity. decamethonium bromide bears us nlm identifiers umls id c0112701 and nci concept code c65365. smiles: c[n+](c)(c)cccccccccc[n+](c)(c)c.[br-].[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. dotefonium bromide. this classification denotes a muscle relaxant with the molecular formula c20h27n2o2s.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier d762286a5n, chemically known as pyrrolidinium, 1-methyl-1-(2-(n-methyl-alpha-2-thienylmandelamido)ethyl)-, bromide but more generally known as dotefonium bromide, which bears us nih compound identifier 71913. european medicines agency schedules dotefonium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06379mig. the term dotefonium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 25 , no. 10 1971, list 11). most nations, for tariff and trade purposes, schedule dotefonium bromide under hs 29349990 and sitc 51579. as of q4 2014, dotefonium bromide remains us fdas preferred term for this commodity. dotefonium bromide bears us nlm identifiers umls id c1880401 and nci concept code c65471. smiles: cn(cc[n+]1(cccc1)c)c(=o)c(c2ccccc2)(c3cccs3)o.[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. doxacurium chloride. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m78tvm3g5z. european medicines agency schedules doxacurium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06380mig. doxacurium chloride generally arises in the molecular formula c56h78cl2n2o16. the term doxacurium chloride is an international non-proprietary name or inn (see world health organization inn reference publication, volume 2, no. 3, 1988, list 28.) most nations, for tariff and trade purposes, schedule doxacurium chloride under hs 29334990 and sitc 51575. doxacurium chloride bears us nlm identifiers umls id c0114872 and nci concept code c65472. smiles: as of q4 2014, doxacurium chloride remains us fdas preferred term for this commodity.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. fenyramidol hydrochloride. this classification denotes a muscle relaxant with the molecular formula c13h14n2o.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier m574v6xqh7, chemically known as benzyl alcohol, alpha-((2-pyridylamino)methyl)-, monohydrochloride but more generally known as fenyramidol hydrochloride, which bears us nih compound identifier 9469. european medicines agency schedules fenyramidol hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub02134mig. most nations, for tariff and trade purposes, schedule fenyramidol hydrochloride under hs 29333999. smiles: c1ccc(cc1)c(cnc2ccccn2)o.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. fenyripol hydrochloride. this classification denotes a muscle relaxant with the molecular formula c12h13n3o.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier r4i084c0no, chemically known as benzyl alcohol, alpha-((2-pyrimidinylamino)methyl)-, monohydrochloride but more generally known as fenyripol hydrochloride, which bears us nih compound identifier 17118. most nations, for tariff and trade purposes, schedule fenyripol hydrochloride under hs 29335995 and sitc 51576. as of q4 2014, fenyripol hydrochloride remains us fdas preferred term for this commodity. fenyripol hydrochloride bears us nlm identifiers umls id c2825401 and nci concept code c80984. smiles: c1ccc(cc1)c(cnc2ncccn2)o.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. hexcarbacholine bromide. this classification denotes a muscle relaxant with the molecular formula c18h40n4o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier nm87thp11p, chemically known as n,n,n,n,n,n-hexamethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecamethylendiammonium dibromid but more generally known as hexcarbacholine bromide, which bears us nih compound identifier 71495. european medicines agency schedules hexcarbacholine bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08034mig. the term hexcarbacholine bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule hexcarbacholine bromide under hs 29241900 and sitc 51471. as of q4 2014, hexcarbacholine bromide remains us fdas preferred term for this commodity. hexcarbacholine bromide bears us nlm identifiers umls id c2825403 and nci concept code c80986. smiles: c[n+](c)(c)ccoc(=o)nccccccnc(=o)occ[n+](c)(c)c.[br-].[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. inaperisone hydrochloride. this classification denotes a muscle relaxant with the molecular formula c16h23no.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 67d70i271p, chemically known as inaperisone hydrochloride, (+/-)-, but more generally known as inaperisone hydrochloride, which bears us nih compound identifier 147524. european medicines agency schedules inaperisone hydrochloride or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08162mig. most nations, for tariff purposes, schedule inaperisone hydrochloride under hs 29339990. smiles: ccc1ccc(cc1)c(=o)c(c)cn2cccc2.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. lanperisone hydrochloride. this classification denotes a muscle relaxant with the molecular formula c15h18f3no.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier jrf22nv56m, chemically known as (-)-lanperisone hydrochloride, but more generally known as lanperisone hydrochloride, which bears us nih compound identifier 198706. european medicines agency schedules lanperisone hydrochloride or its base in its extended eudravigilance medicinal product dictionary or xevmpd under index sub08400mig. most nations, for tariff purposes, schedule lanperisone hydrochloride under hs 29339990. smiles: c[c@h](cn1cccc1)c(=o)c2ccc(cc2)c(f)(f)f.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mephenesin carbamate. this classification denotes a muscle relaxant with the molecular formula c11h15no4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier pad6sxb23n, chemically known as 1,2-propanediol, 3-(o-tolyloxy)-, 1-carbamate (8ci) but more generally known as mephenesin carbamate, which bears us nih compound identifier 10775. most nations, for tariff and trade purposes, schedule mephenesin carbamate under hs 29094990 and sitc 51617. as of q4 2014, mephenesin carbamate remains us fdas preferred term for this commodity. smiles: cc1ccccc1occ(coc(=o)n)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. nelezaprine maleate. this classification denotes a muscle relaxant with the molecular formula c18h21cln2.c4h4o4, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 3q9l107xjb, chemically known as 3-(9-chloro-5,6-dihydro-11-h-pyrrolo(2,1-b))(3)benzazepine-11-ylidine-n,n-dimethyl-1-propanaminebutenedioate but more generally known as nelezaprine maleate, which bears us nih compound identifier 6436129. most nations, for tariff and trade purposes, schedule nelezaprine maleate under hs 29339930 and sitc 51577. as of q4 2014, nelezaprine maleate remains us fdas preferred term for this commodity. nelezaprine maleate bears us nlm identifiers umls id c2825399 and nci concept code c80980. smiles: cn(c)cc/c=c\\1/c2cccn2ccc3c1cc(cc3)cl.c(=c\\c(=o)o)\\c(=o)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. orphenadrine citrate. this classification denotes a muscle relaxant with the molecular formula c18h23no.c6h8o7, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier x0a40n8i4s, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine citrate, which bears us nih compound identifier 4601. european medicines agency schedules orphenadrine citrate in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03546mig. most nations, for tariff and trade purposes, schedule orphenadrine citrate under hs 29221990 and sitc 51461. as of q4 2014, orphenadrine citrate remains us fdas preferred term for this commodity. orphenadrine citrate bears us nlm identifiers umls id c0029310 and nci concept code c47641. smiles: cc1ccccc1c(c2ccccc2)occn(c)c.c(c(=o)o)c(cc(=o)o)(c(=o)o)o.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. orphenadrine hydrochloride. this classification denotes an antimuscarinic agent with the molecular formula c18h23no.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier uby910duxh, chemically known as n,n-dimethyl-2-(o-methyl-.alpha.-phenylbenzyloxy)ethylamine hydrochloride but more generally known as orphenadrine hydrochloride, which bears us nih compound identifier 4601. european medicines agency schedules orphenadrine hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub03547mig. most nations, for tariff and trade purposes, schedule orphenadrine hydrochloride under hs 29221980 and sitc 51461. as of q4 2014, orphenadrine hydrochloride remains us fdas preferred term for this commodity. orphenadrine hydrochloride bears us nlm identifiers umls id c0699481 and nci concept code c78075. smiles: cc1ccccc1c(c2ccccc2)occn(c)c.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. oxydipentonium chloride. this classification denotes a muscle relaxant with the molecular formula c16h38n2o.2cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier vv0b5mp6vi, chemically known as 5,5-bis(trimethylammonium)dipentyl ether dichlorid but more generally known as oxydipentonium chloride, which bears us nih compound identifier 23560. european medicines agency schedules oxydipentonium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09563mig. the term oxydipentonium chloride is an international non-proprietary name. most nations, for tariff and trade purposes, schedule oxydipentonium chloride under hs 29239000 and sitc 51481. as of q4 2014, oxydipentonium chloride remains us fdas preferred term for this commodity. oxydipentonium chloride bears us nlm identifiers umls id c1882246 and nci concept code c66280. smiles: c[n+](c)(c)cccccoccccc[n+](c)(c)c.[cl-].[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. pancuronium bromide. this classification denotes a muscle relaxant with the molecular formula c35h60n2o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier u9ly9y75x2, chemically known as 5.alpha.-androstan-3.alpha.,17.beta.-diol, 2.beta., 16.beta.-dipipecolinio-, dibromide, diacetate but more generally known as pancuronium bromide, which bears us nih compound identifier 4675. european medicines agency schedules pancuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09603mig. the term pancuronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 22, no. 10, 1968, list 8). most nations, for tariff and trade purposes, schedule pancuronium bromide under hs 29333999 and sitc 51574. as of q4 2014, pancuronium bromide remains us fdas preferred term for this commodity. pancuronium bromide bears us nlm identifiers umls id c0030715 and nci concept code c47651. smiles: cc(=o)o[c@h]1c[c@@h]2cc[c@@h]3[c@@h]([c@]2(c[c@@h]1[n+]4(ccccc4)c)c)cc[c@]5([c@h]3c[c@@h]([c@@h]5oc(=o)c)[n+]6(ccccc6)c)c.[br-].[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. pipecuronium bromide. this classification denotes a muscle relaxant with the molecular formula c35h62n4o4.2br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier r6zty81re1, chemically known as 4,4-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1,1-dimethylpiperazinium)dibromide, diacetate (ester) but more generally known as pipecurium bromide, which bears us nih compound identifier 65332. european medicines agency schedules pipecuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub14880mig. the term pipecuronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 33, no. 10 1979, list 19). world health organization schedules pipecurium bromide in its anatomical therapeutic chemical (atc) classification. most nations, for tariff and trade purposes, schedule pipecuronium bromide under hs 29335995 and sitc 51576. as of q4 2014, pipecuronium bromide remains us fdas preferred term for this commodity. pipecuronium bromide bears us nlm identifiers umls id c0206049 and nci concept code c66393. smiles: cc(=o)o[c@h]1c[c@@h]2cc[c@@h]3[c@@h]([c@]2(c[c@@h]1n4cc[n+](cc4)(c)c)c)cc[c@]5([c@h]3c[c@@h]([c@@h]5oc(=o)c)n6cc[n+](cc6)(c)c)c.[br-].[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. rapacuronium bromide. this classification denotes a muscle relaxant with the molecular formula c37h61n2o4.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 65q4qdg4kc, chemically known as piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-3-(acetyloxy)-17-(1-oxopropoxy)-2-(1-piperidinyl)androstan-16-yl)-1-(2-propenyl)-, bromide but more generally known as rapacuronium bromide, which bears us nih compound identifier 177969. european medicines agency schedules rapacuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10260mig. the term rapacuronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 12 no. 2 1999, list 40). most nations, for tariff and trade purposes, schedule rapacuronium bromide under hs 29333999 and sitc 51574. as of q4 2014, rapacuronium bromide remains us fdas preferred term for this commodity. rapacuronium bromide bears us nlm identifiers umls id c0753790 and nci concept code c66509. smiles: ccc(=o)o[c@h]1[c@h](c[c@@h]2[c@@]1(cc[c@h]3[c@h]2cc[c@@h]4[c@@]3(c[c@@h]([c@h](c4)oc(=o)c)n5ccccc5)c)c)[n+]6(ccccc6)cc=c.[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. rocuronium bromide. this classification denotes a muscle relaxant with the molecular formula c32h53n2o4.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier i65mw4ofhz, chemically known as 1-allyl-1-(3alpha,17beta-dihydroxy-2beta-morpholino-5alpha-androstan-16beta-yl)pyrrolidinium bromide, 17-acetate but more generally known as rocuronium bromide, which bears us nih compound identifier 60695. european medicines agency schedules rocuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10353mig. the term rocuronium bromide is an international non-proprietary name or inn (see world health organization inn reference publication, volume 6, no, 3 1992, list 32). world health organization schedules rocuronium bromide in its anatomical therapeutic chemical (atc) classification. most nations, for tariff and trade purposes, schedule rocuronium bromide under hs 29349990 and sitc 51579. as of q4 2014, rocuronium bromide remains us fdas preferred term for this commodity. rocuronium bromide bears us nlm identifiers umls id c0591463 and nci concept code c47709. smiles: cc(=o)o[c@h]1[c@h](c[c@@h]2[c@@]1(cc[c@h]3[c@h]2cc[c@@h]4[c@@]3(c[c@@h]([c@h](c4)o)n5ccocc5)c)c)[n+]6(cccc6)cc=c.[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. stercuronium iodide. this classification denotes a muscle relaxant with the molecular formula c26h43n2.i, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier k1477r7ddr, chemically known as (cona-4,6-dienin-3beta-yl)dimethylethylammonium iodide but more generally known as stercuronium iodide, which bears us nih compound identifier 71924. european medicines agency schedules stercuronium iodide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10646mig. the term stercuronium iodide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule stercuronium iodide under hs 29339990 and sitc 51577. as of q4 2014, stercuronium iodide remains us fdas preferred term for this commodity. stercuronium iodide bears us nlm identifiers umls id c2983929 and nci concept code c90895. smiles: cc[n+](c)(c)[c@h]1cc[c@@]2([c@h]3cc[c@]45cn([c@h]([c@h]4cc[c@h]5[c@@h]3c=cc2=c1)c)c)c.[i-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. suxethonium chloride. this classification denotes a muscle relaxant with the molecular formula c16h34n2o4.2cl, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier u5026h7s5s, chemically known as succinic acid, diester with choline iodide but more generally known as suxethonium chloride, which bears us nih compound identifier 5314. european medicines agency schedules suxethonium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub10788mig. the term suxethonium chloride is an international non-proprietary name. most nations, for tariff and trade purposes, schedule suxethonium chloride under hs 29239000. as of q4 2014, suxethonium chloride remains us fdas preferred term for this commodity. suxethonium chloride bears us nlm identifiers umls id c2700609 and nci concept code c74283. smiles: cc[n+](c)(c)ccoc(=o)ccc(=o)occ[n+](c)(c)cc.[cl-].[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. tolperisone hydrochloride. this classification denotes a muscle relaxant with the molecular structure c16h23no.clh, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier, 8z075k2tig chemically known as 2,4-dimethyl-3-piperidinopropiophenone hydrochloride, but more commonly known as tolperisone hydrochloride, which bears us nih compound identifier 92965. european medicines agency schedules tolperisone hydrochloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub04912mig. most nations, for tariff and trade purposes, schedule tolperisone hydrochloride under hs 29333999 and sitc 51574. as of q4 2014, tolperisone hydrochloride remains us fdas preferred term for this commodity. tolperisone hydrochloride bears us nlm identifiers umls id c1564420 and nci concept code c84220. smiles: cc1ccc(cc1)c(=o)c(c)cn2ccccc2.cl.. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. tubocurarine chloride. this classification denotes a muscle relaxant, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 900961z8vr. european medicines agency schedules curare in its extended eudravigilance medicinal product dictionary or xevmpd under index sub49132. tubocurarine chloride generally arises in the molecular formula c37h41n2o6.cl.clh.5h2o. the term tubocurarine chloride is a united states homeopathic pharmacopoeia name designation. most nations, for tariff and trade purposes, schedule tubocurarine chloride under hs 29399900 and sitc 54149. as of q4 2014, tubocurarine chloride remains us fdas preferred term for this commodity. tubocurarine chloride bears us nlm identifiers umls id c0282372 and nci concept code c47777. smiles: cn1ccc2cc(c3cc2[c@@h]1cc4ccc(cc4)oc5c6c(cc(c5o)oc)cc[n+]([c@@h]6cc7ccc(c(c7)o3)o)(c)c)oc.o.o.o.o.o.cl.[cl-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. vecuronium bromide. this classification denotes a muscle relaxant with the molecular formula c34h57n2o4.br, a preparation that us fda regulates as an active ingredient or moiety under unique ingredient identifier 7e4php5n1d, chemically known as 5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate but more generally known as vecuronium bromide, which bears us nih compound identifier 39764. european medicines agency schedules vecuronium bromide in its extended eudravigilance medicinal product dictionary or xevmpd under index sub00029mig. the term vecuronium bromide is an international non-proprietary name. most nations, for tariff and trade purposes, schedule vecuronium bromide under hs 29333999 and sitc 51574. as of q4 2014, vecuronium bromide remains us fdas preferred term for this commodity. vecuronium bromide bears us nlm identifiers umls id c0042435 and nci concept code c47782. smiles: cc(=o)o[c@h]1c[c@@h]2cc[c@@h]3[c@@h]([c@]2(c[c@@h]1n4ccccc4)c)cc[c@]5([c@h]3c[c@@h]([c@@h]5oc(=o)c)[n+]6(ccccc6)c)c.[br-].. "
"neuromuscular blocking agents. this classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.. mivacurium chloride. this classification denotes a muscle relaxant with the molecular formula c58h80n2o14.2cl, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 600zg213c3, chemically known as (r)-1,2,3,4-tetrahydro-2-(3-hydroxypropyl)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)isoquinolinium chloride, (e)-4-octenedioate (2:1) but more generally known as mivacurium chloride, which bears u.s. national institutes of health compound identifier 5281080. european medicines agency schedules mivacurium chloride in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09014mig. the term mivacurium chloride is an international non-proprietary name or inn (see world health organization inn reference publication, volume 2, no. 3, 1988, list 28). world health organization schedules mivacurium chloride in its anatomical therapeutic chemical (atc) classification and its who-dd or drug dictionary.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. . "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. chlordiazepoxide/methscopolamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. atropine/hyoscyamine/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. atropine/hyoscyamine/phenobarbital/scopolamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. atropine/hyoscyamine/scopolamine/simethicone. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. atropine/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. atropine/phenobarbital/scopolamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. belladonna/butabarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. belladonna/charcoal. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. belladonna/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. chlordiazepoxide/clidinium. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. dicyclomine/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. hydroxyzine/oxyphencyclimine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. hyoscyamine/passion flower/phenobarbital/scopolamine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. hyoscyamine/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. hyoscyamus/passion flower/phenobarbital/valerian. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. hyoscyamus/phenobarbital. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination antimuscarinic and antipasmodics. this classification denotes combination drugs that bind to but do not activate muscarinic receptors (or cholinergic receptors that prefer muscarine rather than nicotine), and thus block actions of endogenous acetylcholine, hence the term antimuscarinics. antimuscarinics affect the iris and ciliary muscle of the eye, heart and blood vessels, respiratory tract secretions, gastrointestinal system, salivary glands, urinary bladder tone, and the central nervous system. typical combination antimuscarinic and antipasmodic constituents are atropine, belladonna, chlordiazepoxide, dicyclomine, hydroxyzine, hyoscyamine, hyoscyamus, and meprobamate.. meprobamate/tridihexethyl. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ga802. this va drug class (ga802) classifies this compound as belonging to the group antimuscarinic/antipasmodic combinations.. "
"combination neuromuscular blocking agents. this classification denotes combination drugs and preparations that interrupt transmission of nerve impulses at the skeletal neuromuscular junction and which therefore bear the name neuromuscular blocking agents. typical combination neuromuscular blocking agent constituents are mivacurium chloride and dextrose.. . "
"combination neuromuscular blocking agents. this classification denotes combination drugs and preparations that interrupt transmission of nerve impulses at the skeletal neuromuscular junction and which therefore bear the name neuromuscular blocking agents. typical combination neuromuscular blocking agent constituents are mivacurium chloride and dextrose.. dextrose/mivacurium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ms300. this va drug class (ms300) classifies this compound as belonging to the group neuromuscular blocking agents.. "
"combination parasympathomimetics (cholinergics). this classification denotes combination drugs and preparations that mimic the effects of parasympathetic nervous system activity and which have affects on cholinergic systems and/or the acetylcholine life-cycle, and which therefore bear the terms parasympathomimetics and cholinergics. typical of this class is the drug atropine. typical combination parasympathomimetic or cholinergic constituents are edrophonium and sodium chloride.. . "
"combination parasympathomimetics (cholinergics). this classification denotes combination drugs and preparations that mimic the effects of parasympathetic nervous system activity and which have affects on cholinergic systems and/or the acetylcholine life-cycle, and which therefore bear the terms parasympathomimetics and cholinergics. typical of this class is the drug atropine. typical combination parasympathomimetic or cholinergic constituents are edrophonium and sodium chloride.. atropine/edrophonium. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class au300. this va drug class (au300) classifies this compound as belonging to the group parasympathomimetics (cholinergics).. "
"combination parasympathomimetics (cholinergics). this classification denotes combination drugs and preparations that mimic the effects of parasympathetic nervous system activity and which have affects on cholinergic systems and/or the acetylcholine life-cycle, and which therefore bear the terms parasympathomimetics and cholinergics. typical of this class is the drug atropine. typical combination parasympathomimetic or cholinergic constituents are edrophonium and sodium chloride.. metoclopramide/sodium chloride. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class au300. this va drug class (au300) classifies this compound as belonging to the group parasympathomimetics (cholinergics).. "
"combination parasympathomimetics (cholinergics). this classification denotes combination drugs and preparations that mimic the effects of parasympathetic nervous system activity and which have affects on cholinergic systems and/or the acetylcholine life-cycle, and which therefore bear the terms parasympathomimetics and cholinergics. typical of this class is the drug atropine. typical combination parasympathomimetic or cholinergic constituents are edrophonium and sodium chloride.. dimethicone + metoclopramide. prevention of postoperative nausea and vomiting or chemotherapy. "
"combination skeletal muscle relaxants. this classification denotes combination drugs and preparations that operate on skeletal muscle, sometimes called neuromuscular agents, though more commonly skeletal muscle relaxants. typical combination skeletal muscle relaxant constituents are carisoprodol, chlorzoxazone, and methocarbamol.. . "
"combination skeletal muscle relaxants. this classification denotes combination drugs and preparations that operate on skeletal muscle, sometimes called neuromuscular agents, though more commonly skeletal muscle relaxants. typical combination skeletal muscle relaxant constituents are carisoprodol, chlorzoxazone, and methocarbamol.. acetaminophen/chlorzoxazone. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf) which falls under va drug class ms200. this va drug class (ms200) classifies this compound as belonging to the group skeletal muscle relaxants. the first component of this combination drug is an analgesic and antipyretic with the molecular formula c8h9no2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier 362o9itl9d, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears u.s. national institutes of health compound identifier 1983. acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate. the european medicines agency schedules acetaminophen in its extended eudravigilance medicinal product dictionary or xevmpd under index sub09611mig. the world health organization schedules acetaminophen in its anatomical therapeutic chemical (atc) classification. the second component of this combination drug is a muscle relaxant with the molecular formula c7h4clno2, a preparation that us fda recognizes as an active ingredient or moiety under unique ingredient identifier h0de420u8g, chemically known as 2-benzoxazolinone, 5-chloro- but more generally known as chlorzoxazone, which bears u.s. national institutes of health compound identifier 2733. the european medicines agency schedules chlorzoxazone in its extended eudravigilance medicinal product dictionary or xevmpd under index sub06215mig. the term chlorzoxazone is an international non-proprietary name. the world health organization schedules chlorzoxazone in its anatomical therapeutic chemical (atc) classification.. "
"combination skeletal muscle relaxants. this classification denotes combination drugs and preparations that operate on skeletal muscle, sometimes called neuromuscular agents, though more commonly skeletal muscle relaxants. typical combination skeletal muscle relaxant constituents are carisoprodol, chlorzoxazone, and methocarbamol.. aspirin/caffeine/orphenadrine. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ms200. this va drug class (ms200) classifies this compound as belonging to the group skeletal muscle relaxants.. "
"combination skeletal muscle relaxants. this classification denotes combination drugs and preparations that operate on skeletal muscle, sometimes called neuromuscular agents, though more commonly skeletal muscle relaxants. typical combination skeletal muscle relaxant constituents are carisoprodol, chlorzoxazone, and methocarbamol.. aspirin/carisoprodol. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ms200. this va drug class (ms200) classifies this compound as belonging to the group skeletal muscle relaxants.. "
"combination skeletal muscle relaxants. this classification denotes combination drugs and preparations that operate on skeletal muscle, sometimes called neuromuscular agents, though more commonly skeletal muscle relaxants. typical combination skeletal muscle relaxant constituents are carisoprodol, chlorzoxazone, and methocarbamol.. aspirin/methocarbamol. this classification denotes a combination drug defined by the u.s. department of veterans affairs in its (vas) national drug file (ndf), which falls under va drug class ms200. this va drug class (ms200) classifies this compound as belonging to the group skeletal muscle relaxants.. "
